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Abstract
A Simulation-based Approach to Study Rare
Variant Associations Across the Disease Spectrum
by
Rosa C. Banuelos
Although complete understanding of the mechanisms of rare genetic variants in dis-
ease continues to elude us, Next Generation Sequencing (NGS) has facilitated signifi-
cant gene discoveries across the disease spectrum. However, the cost of NGS hinders
its use for identifying rare variants in common diseases that require large samples. To
circumvent the need for larger samples, designing efficient sampling studies is crucial
in order to be able to detect potential associations. This research therefore evalu-
ates sampling designs for rare variant-quantitative trait association studies. More
specifically, a statistical framework is presented such that designs based on selective
sampling are properly accounted for. This work also assesses the effects on power that
sampling individuals from existing public cohorts can have on the design. Performing
simulations and evaluating common and unconventional sampling schemes results in
several noteworthy findings. Specifically, the extreme-trait design is the most power-
ful design for analyzing quantitative traits. This research shows that sampling more
individuals from the extreme of clinical interest does not increase power.
Sampling design can have a greater role in gene discovery for monogenic diseases as
the focus moves away from family data to population-based data, in part due to the
iii
advancements in NGS. These advances have facilitated approaches based on variant
filtering, which have served as a “proof-of-concept” approach for the discovery of
disease-causing genes in Mendelian traits. Still formal statistical methods have been
lacking in this area. However, combining variant filtering schemes with existing rare
variant association tests is a practical alternative. In this work, a variant filtering
step is implemented prior to performing rare variant association testing in Mendelian
traits. Specifically, six burden-based rare variant tests are evaluated in the presence
of genetic heterogeneity and genotyping errors. This research shows that with low
locus heterogeneity, these tests are powerful for testing association. With the excep-
tion of the weighted sum statistic (WSS), the remaining tests were very conservative
in preserving the type I error when the number of affected and unaffected individuals
was unequal. The WSS, on the other hand, had inflated type I error as the number
of unaffected individuals increased.
The framework presented can serve as a catalyst to improve sampling design and to
develop robust statistical methods for association testing.
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Chapter 1
Introduction
Advances in Next generation sequencing (NGS) technologies have advanced our knowl-
edge of many Mendelian and common diseases, in particular understanding the role
of rare genetic variants in the etiology of disease. However, it is still relatively ex-
pensive to generate sequence data at the large scale required for many statistical
applications. To circumvent the need of larger samples for common diseases with an
underlying quantitative trait (QT), two strategies can be considered in the study de-
sign: sampling individuals with extreme trait values and utilizing publically available
phenotyped cohorts. Analyzing the extremes of QT distributions was described ear-
lier by Lander and Botstein (1989) for animal breeding studies. Lander and Botstein
(1989) reported that selecting the progeny with extreme QTs provided most of the
information for linkage [50]. More recently, Cohen et al. (2004) resequenced genes in
individuals in only the upper and lower tails of the LDL cholesterol distribution and
showed that individuals in each of the tails harbored different rare genetic variants
than those in the opposite tail [17]. Freely available public cohort databases that
contain thorough phenotypic and genotype information on thousands of individuals
is also a viable approach to acquire large samples as these individuals could be part
of the comparison group or serve as controls.
1
2New rare variant association methods and spin-offs of existing ones continue to emerge
at a fast pace for analyzing complex traits. Yet a very limited number of methods
beyond traditional linkage analysis for Mendelian traits exists, even though more
than half of the culprit genes for such traits remain unknown. The difficulties of gene
mapping in Mendelian traits result because such traits are very rare and there is a
need to obtain sufficient families to observe cosegregation. A successful approach to
finding disease-causing genes has been through resequencing or targeted resequencing
of genetic regions such as the exome in a single affected individual or even a handful of
individuals. Exome sequencing coupled with variant filtering approaches that reduce
the list of probable disease-causing genes has produced significant genetic discoveries,
as is the case for the MLL2 gene in Kabuki syndrome [73] and the DHODH gene
in Miller syndrome [74]. However, such variant filtering approaches are regarded as
“proof-of-principle” without formal statistical methods to back them up.
Thesis Outline
The remainder of this thesis is divided into four chapters. Chapter 2 provides a
background and literature review of the major advancements in NGS and statistical
methods developed for rare variant association testing in both common and Mendelian
diseases. Specifically, I discuss two predominant classes of association tests for com-
plex traits: burden-based and directional tests. I also discuss selective sampling for
quantitative traits. I close chapter 2 by discussing traditional and recent gene map-
ping approaches for Mendelian traits and overall difficulties is finding rare genetic
variants.
In chapter 3, a statistical framework is presented for selective sampling designs for
rare variant-complex QT associations. By performing thorough simulations, type I
error and power are evaluated for different sampling schemes from the general pop-
ulation and fixed-size cohorts. The primary finding is that the extreme-trait design
3is the most powerful design, with only a mild type I error inflation, within an ε of α.
In addition, when carrying out selective sampling from an existing cohort, selecting
more individuals from the tail of clinical interest does not increase power.
Chapter 4 evaluates the performance of six burden-based rare variant association tests
for rare-variant Mendelian-trait association after a variant filtering step. Specifically,
the type I error and power of the test are formally assessed via a simulation study
of both dominant and recessive traits with different levels of genetic heterogeneity.
To allow for noise from the sequencing and genotyping process, the proportions of
causal and neutral variants that are missing are also varied. When including an equal
number of affected and unaffected individuals, the six tests conservatively preserve
the type I error. Finally, the tests were sufficiently powerful when a small fraction of
the causal variants are missing and there is low locus heterogeneity.
In chapter 5, I provide a summary of the major contributions of this thesis and discuss
future research that can stem from my dissertation work. I also discuss some of the
difficulties in association testing for both Mendelian and complex traits.
Chapter 2
Background and Literature Review
The spectrum of human traits ranges from Mendelian to multifactorial traits. Mendelian
traits usually result from a mutation in a single gene and are often qualitative with
a clear cut outcome (present/not present). Multifactorial traits take on qualitative
or quantitative values and are influenced by a mix of genetic and environmental
factors and possibly interactions among them. There is no clear boundary for sepa-
rating single-gene disorders from multifactorial traits [57] and there are multifactorial
traits with monogenic forms. Figure 2.1 illustrates this point for hypertriglyceridemia
(HTG), a metabolic lipid disorder, that can have monogenic or polygenic forms based
on the levels of plasma triglycerides (TG) [42].
Because the makeup of multifactorial traits is more involved, these type of traits are
better known as complex traits. Examples of such traits include height, body mass
index (BMI), and cancer. Complex traits that are of primary public health inter-
est are common diseases in the general population like cardiovascular disease (CVD)
which has high mortality and elevated health care cost in the U.S. [68]. Unraveling
the makeup of common diseases, in particular their genetic factors, continues to be a
high priority to decrease the public health burden.
4
5Figure 2.1: Image of the disease spectrum of HTG. This image illustrates that the
most extreme levels of triglycerides can lead to Mendelian-forms of HTG. Reprinted
with permission from Elsevier: BBA-Molecular & Cell Biology of Lipids, 1821(15),
833-42, copyright (2012) [42].
In the past decade, genome-wide association studies (GWAS) have been the lead-
ing approach for searching for culprit genes in common diseases. GWAS are often
metaphorically referred to as “fishing expeditions”[44] because the entire genome is
scanned for genetic variants without a priori knowledge of a candidate gene. Recent
GWAS are able to interrogate millions of Single Nucleotide Polymorphisms (SNPs) in
thousands of individuals. One of the most notable successes of GWAS came in 2005
with the reported association between complement factor H (CFH ) gene on chromo-
some 1 and age-related macular degeneration (MD) [45]. The association between
CHF and MD is of particular interest because it required only 96 individuals and this
association has been replicated, which are both unusual for GWAS. As of July 16,
2012 the National Human Genome Research Institute (NHGRI) has reported more
than 1,300 papers on associations between 6,596 SNPs and more than eighty traits,
many of which are replication studies [35].
62.1 Competing Hypothesis on Common Disease
Etiology
GWAS are driven primarily by the Common Disease/Common Variant (CD/CV)
hypothesis, which states that the variability in complex traits result from variants
with small to moderate effect size that are common in the population [49]. These
common variants have a minor allele frequency (MAF) of 1% [12] or more in the
general population. The classical example used to support CD/CV is the association
of Alzheimer’s disease and the Apolipoprotein E (APOE ) gene. The frequency of the
APOE -ε4 allele in the U.S. ranges between 15-30% and is associated with 50% of
Alzheimer cases [93].
Based on twin studies, many common diseases have a heritability between 40% and
90% [58] yet the majority of common variants identified by GWAS have not been able
to explain more than 20% of the genetic variability in many complex diseases [62].
Many of these common genetic variants have been associated with the trait under
study, yet they often are not the true causal variant, i.e., the variant that alters the
function of a gene and in turn alters the phenotype. If the discovered variant is causal,
it may be necessary but alone is not sufficient to alter the trait outcome. The reason
is that common variants typically have small effect sizes with odds ratios (ORs) no
greater than 1.5 [61].
This has lead to a search for more contributing factors to the remaining proportion
of genetic variability or “missing heritability” of complex traits [60]. One option has
been to focus on uncommon variants, in particular to rare variants. The increased in-
terest in the role of rare variants results from an alternative hypothesis to the CD/CV,
the Common Disease/Rare Variant (CD/RV) hypothesis. CD/RV states that many
variants with MAF less than 1% underlie common disease [87], and thus explain a
7greater proportion of the genetic variability. These variants alone may be rare but as
a group they can be common in the population. Since rare variants are more likely to
be nonsynonymous [12] and functional [31], it is believed that they will have a greater
effect on common diseases.
While the study of rare variants is not new, the rekindled interest in them has amassed
several findings. The association between high density lipoprotein cholesterol (HDL-
C) and multiple rare variants in the NPC1L1 gene [17] is one of the first to be referred
to. Another successful association includes one reported between Type 1 Diabetes
(T1D) and rare variants in the IFIF1 gene [70].
A recent conjecture suggests that the signal that has been picked up by GWAS at loci
with common variants likely results from a rare variant nearby creating what is called
a synthetic association [20]. The synthetic association hypothesis is plausible because
rare and common variants can reside on the same loci. However, this hypothesis is
still being debated. In addition, GWAS have produced notable gene discoveries as
discussed earlier.
Rare variants are not amenable to detection by the technology used for common
variants. For common variants, there exists comprehensive databases for selecting
tagSNPs based on the results from projects such as the HapMap, which were con-
ducted to catalogue human variation with a MAF of at least 1%. Such catalogues
were key to developing reliable SNP chips to detect common variants. While projects
are underway to create similar databases for rare variants, alternative detection tech-
nology will be necessary.
82.2 Next Generation Sequencing (NGS)
Tagging markers based on linkage disequilibrium (LD), i.e. allelic association, as done
for GWAS is not suitable for rare variants because it is unlikely that more than one
rare variant resides on the same haplotype. Rare variants must be searched for directly
in an unbiased manner using sequencing technology. Sequencing refers to determining
the exact DNA base (A, T, G, or C) ordering in a genetic region. In 1977, Frederick
Sanger developed an efficient sequencing approach based on a dideoxy terminator
technique [92]. The ABI capillary sequencing machines based on the Sanger method
have been widely used. Sanger sequencing had been the primary sequencing approach
until the mid-2000’s. Next Generation Sequencing (NGS) technology emerged in 2005
allowing for massive parallel sequencing [30] in less time and a lower cost than Sanger
sequencing. The first human genome sequenced using NGS took ∼ 4 months and
cost about $1 million in comparison to the four years and $100 million required to
complete the first human genome using the Sanger method [89].
2.2.1 Current Sequencing Technologies
NGS or what is now called second-generation sequencing technology has enabled
high-throughput sequencing of whole human genomes. Sequencing a human genome,
which consists of ∼ 3.2 × 109 bp [29], using NGS takes an average of one week [96].
The leading companies for NGS include Roche, Illumina and Applied Biosystems
(ABI). Roche’s and Illumina’s sequencing technologies rely on synthesis-based se-
quencing. The SOLiDa by ABI is based on a ligation method. More recent sequenc-
ing technology, or third-generation sequencing methods are based on single-molecule
sequencing techniques [13] and are currently developed by Helicos BioSciences, Pa-
cific Biosciences, Oxford Nanopore and Ion Torrent. Single molecule sequencing was
originally introduced by Helicos BioSciences [34]. While Oxford Nanopore also uses
single-molecule sequencing, it’s goal is to “develop the first label-free, single molecule
9DNA sequencing technology” [80]. Table 2.1 provides a list of common sequencing
technologies and key features of the employed sequencing instruments. In summary,
454 gives greater read length and is the most expensive. While Illumina and AB are
most cost-effective, they are more error prone due to their shorter reads [13].
As of October 2012, NHGRI reports that sequencing the entire human genome is
estimated to cost $6,6181 [101]. While the cost has dramatically decreased in com-
parison to the first genome sequenced using NGS, large scale studies are infeasible
because of the large sample sizes required to detect low frequency variants. Alter-
natives to whole-genome sequencing include targeted sequencing or re-sequencing of
selected genes and other regions of the genome.
2.2.2 Exome Sequencing
A gene is made up of a 5’-untraslated region (5-UTR), introns, exons, and 3’-UTR
as illustrated in figure 2.2. There are ∼20,000-25,000 genes in the human genome.
Of particular imporance are the protein-coding regions of genes, or exons, because
these regions are more likely to harbor functional rare variants and more than 85%
of disease-causing variants are located in this region [16]. All exons compromise
about 1 to 2% of the human genome and collectively all exons are dubbed the exome.
The exome contains ∼180,000-200,000 exons. In any one individual there can be be-
tween 15,000 to 20,000 variants per exome [75], with estimates increasing to 24,000
in African Americans [6].
Exome sequencing, or sequencing only the exons and flanking introns, is carried out
by using reagent kits like Illunima’s TruSeq, Nimblegen SeqCap EZ exome or Agilent’s
SureSelect Target Enrichment kits on the platforms discussed in the previous section.
Exome sequencing offers a feasible alternative to whole-genome sequencing because
1This estimate reflects the “production costs” as described at www.genome.gov/sequencingcosts
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Figure 2.2: Image of exons and introns in a gene. National Institutes of Health.
National Human Genome Research Institute. “Talking Glossary of Genetic Terms.”
Retrieved July 24, 2010, from http://www.genome.gov/glossary [76].
it’s lower sequencing cost translate to an increase in the sampling potential by upto
ten-fold. Exome sequencing in as little as one to ten individuals has yielded novel gene
discoveries. By sequencing the exomes of four individuals, Ng et al. (2009) reported
the discovery of causal variants in the DHODH gene responsible for Miller syndrome
[74] and shortly after this group also reported the identification of the MLL2 gene
causing Kabuki syndrome [73].
2.2.3 Limitations of NGS and Exome Sequencing
Sequencing technology would ideally cover all variant types at high coverage and al-
most error free [14]. Unlike Sanger sequencing, NGS has a greater error rate and there
is sill no consensus on targets or genotype calling [6, 98]. While most sequencing sys-
tems have an accuracy rate above 99%, newer technology such as Oxford Nanopore’s
have an accuracy of 96% [80]. Many discoveries from NGS are validated using Sanger
sequencing. To do away with such a validation step would require NGS to reach
the high fidelity obtained by microarray chips. The high genotyping call rates of
genotyping chips makes them vital in gene discovery and may often be preferred over
exome or whole genome sequencing [28]. Recently, NIH’s Undiagnosed Disease Pro-
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gram (UDP) showed that genotyping chips were pivotal in diagnosing rare conditions
in which a homozygous state or recessive mode of inheritance was suspected [27]. For
the purpose of detecting rare variant associations with complex traits, genotyping
chips will not be an option until rare variation is properly catalogued. NGS poses
a large financial constraint that is expected to be alleviated with the coming of the
$1,000 genome. Until then, exome sequencing will remain a viable alternative. While
exome sequencing reduces costs, it is primarily limited because it only covers ∼ 1−2%
of the entire genome and up to 10% of the exome can be missed or not properly
covered [6]. Non-coding regions can also harbor important functional variants. For
example, variants in the introns of gene FGFR2 are involved in gene regulation and
are associated with increased risk for breast cancer [22]. In addition to the limita-
tions posed by technology, there is still a dire need for statistical methodology and
sampling designs to link actual genetic discoveries to phenotypes.
2.3 Rare Variant Association Methods
Rare variants by definition have a low allele frequency which makes population-based
methods difficult to implement. In the past five years many different flavors of rare-
variant association methods have been introduced, ranging from contingency table-
based tests to more complicated methods such as Bayesian Hierarchical models. Here,
I present the tests that serve as the foundation to many of newer tests or tests that are
commonly used. The primary tests used for rare variant association can be broadly
classified as Burden (i.e., collapsing) or Directional tests. Burden tests assess the
number of rare variants carried in affected individuals relative to the number in con-
trols. Directional tests are those that account for whether a variant has a risk or a
protective effect. For both type of tests, there can be a weighting mechanism that ac-
counts for variant enrichment in cases or that weighs based on functional information
about the variant. Below, I introduce notation that will be consistent for the methods
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described in the following sections. I assign the subscript i for individuals {1, . . . , n},
j for variants {1, . . . ,m}, and k for groups {1, . . . l}. The number of affected/case
individuals (1) is denoted by n1 and similarly n0 for unaffected/control individuals
(0).
The quantitative trait is denoted by Y while binary traits such as affection or case-
control status are denoted by D. X represents the non-genetic covariates with coef-
ficients β. Genotype information is denoted by gij and can take values {0,1,2} for
the number of alleles individual i carries at site j. G⃗ is the vector of genotypes or
multi-site genotypes, e.g., the vector for individual i is G⃗i = (g1i, g2i, . . . , gmi) for m
variant sites. Ij(i) is the indicator function for presence of at least one minor allele
in individual i at site j. Finally, weights are designated by w.
2.3.1 Burden Tests
Collapsing tests are based on creating groups to analyze rare variants and create
“super-variants” [8]. For these types of tests, it is important to determine the best
way to collapse variants. Usually this is by gene or MAF.
The Cohort Allelic Sums Test (CAST)
The CAST by Morgenthaler and Thilly (2007) was the first method to suggest that
mutations be collapsed into groups. CAST is based on comparing the carrier fre-
quencies between affected and unaffected individuals. For a pre-specified grouping
criteria, such as gene, the collapsing takes place where an individual carries at least
one mutation at a gene. The carrier frequencies between affected and unaffected in-
dividuals can be compared using Fisher’s exact test or a Chi-square test [66].
Fisher’s exact test assumes that the marginals of a contingency table are fixed. If we
let A denote the number of affected individuals with one or more rare variants, then for
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0 ≥ 1
Affected (1) a b n1
Unaffected (0) c d n0
a + c b + d n
Table 2.2: 2 × 2 Contingency Table
a 2× 2 contingency table (as in table 2.2), the probability of observing O = b affected
individuals with one or more variants can be computed using the hypergeometric
distribution:
Prob(A = b) =
⎛⎜⎝ n1b
⎞⎟⎠
⎛⎜⎝ n0d
⎞⎟⎠⎛⎜⎝ nb + d
⎞⎟⎠
.
The p-value is then calculated as the sum of probabilities of tables where one would
observe b or more affected individuals with one or more variants, ∑
A≥bP (A∣(b + d)).
CAST is straightforward to implement. A limitation of CAST is that the causal
variant would not be easily discerned due to the collapsing. In addition, Fisher’s
exact test is conservative.
Combined Multivariate and Collapsing (CMC)
Li and Leal (2008) extended CAST to a multivariate setting in the CMC method for
detecting rare variants. This method also collapses the genotypes for affected and
unaffected individuals as CAST. While typically only rare variants with minor allele
frequency (MAF) ≤ 0.01 are collapsed, CMC allows for common variants to be in
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their own group. Hypothesis testing can be carried out using a multivariate test such
as Hotelling’s T 2 [53].
The CMC is implemented as follows:
First, m markers are grouped into l groups (l <m). Let G⃗1j = (G1j1, . . . ,G1jn1)T be the
vector of genotypes at site j for affected individuals. Similarly G⃗0j = (G0j1, . . . ,G0jn0)T
is defined for unaffected individuals. The proportion of individuals for each site j is
summarized in G¯0j = 1n0 n0∑
i=1G0ji and G¯1j = 1n1 n1∑i=1G1ji. All sites for affected and unaffected
are summarized in G¯0 = (G¯01, . . . , G¯0m) and G¯1 = (G¯11, . . . , G¯1m).
To test all variants simultaneously, Hotelling’s T 2 (1931) is used to obtain the test
statistic:
T 2 = n0n1
n
(G¯0 − G¯1)TS−1(G¯0 − G¯1)
with pooled covariance matrix (S):
S = 1
n − 2 n0∑j=1(G⃗0j − G¯0)(G⃗0j − G¯0)T + n1∑j=1(G⃗1j − G¯1)(G⃗1j − G¯1)T .
Hotelling’s T 2 is asymptotically distributed as an F distribution, n−m−1m(n−2)T 2∼˙Fm,n−m−1
[53].
The strengths of the CMC is that power can be computed analytically (has a closed
form distribution) and common variants can be included in their own group. The
drawback is that there can be a loss of power by collapsing variants with protective
and risk effects.
Weighted Sum Statistic (WSS)
Madsen and Browning (2009) proposed the WSS, a groupwise test for rare variant
association. Variants are grouped according to gene or some other grouping scheme
and weights are assigned based on the variant frequency in controls (0). Each indi-
vidual is assigned a genetic score based on their variant load. The test statistic is
based on the ranking of the genetic score for cases [59].
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Implementation steps for WSS:
1. For each variant j in a group with mj variants, a weight is calculated as:
wˆj = √nj ⋅ qj(1 − qj) where qj = m0j + 1
2n0j + 2 .
For SNP j, m0j and n
0
j represent the number of mutant alleles in controls and
the number of controls genotyped for SNP j, respectively.
2. For each individual i, a genetic score is calculated across all variants sites:
γi = M∑
j=1
gij
wˆj
.
3. Based on the γi’s, individuals are ranked and only the ranks of affected (A)
individuals are summed:
x =∑
i∈A rank(γi).
4. Affection status is permuted k times repeating the previous three steps.
5. The ranks of the permuted data are averaged (µˆrank) and N(0,1) standardized:
z = x − µˆrank
σˆ
.
A limitation of the WSS is that asymptotic-based methods are not appropriate for
rare variants and permutation-based approaches are computationally expensive.
Variable Threshold (VT)
The VT by Price et al. (2010) is a method to group variants using a variable allele-
frequency threshold rather than a fixed threshold. The premise of VT is that there
exists an unknown threshold that separates functional variants from neutral and/or
non-causal variants. The optimal threshold is selected by maximizing the test statistic
over the entire threshold range. VT is implemented in a regression framework where
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the trait is a function of genotype scores determined by the variable threshold. VT
allows for functional information to be incorporated into a weighting scheme similar
to the WSS. Significance can be evaluated using permutation or based on a standard
normal approximation [86].
VT implementation:
The VT score is denoted by:
m∑
j=1
n∑
i=1wjCijyi, where Cij is the number of alleles at SNP j.
For each threshold T considered, the z-score is computed and normalized:
z(T ) =
m∑
j=1
n∑
i=1wTj Cij(yi − y¯)¿ÁÁÀ m∑
j=1
n∑
i=1(wTj Cij)2
∝ N(0,1).
The VT test statistic is taken as the maximum z(T ) over all thresholds T and is de-
noted by zmax. Significance is assessed by the ratio of the number of zmax values that
exceed the test statistic for the unpermuted data out of all permutations performed.
Functional information can be incorporated through the weights by using the proba-
bility that an allele with frequency p is functional (ϕ(p)) or by considering a variant’s
Poly-Phen score (S):
wj =
⎧⎪⎪⎪⎪⎪⎪⎨⎪⎪⎪⎪⎪⎪⎩
1 for nonsense, etc. variants
0.5 for common variants
P (S) for variant with MAF < 1%
where P (S)=P(S classifies variant as functional) [86].
The VT offers several advantages over other methods. It can be used for qualitative or
quantitative traits and it allows for other weighting schemes to be used. For example,
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if wj = 1√pj(1−pj) , then the WSS by Madsen and Browning is recovered. In addition,
methods based on a fixed threshold can easily be obtained by defining the VT score
as follows:
m∑
j=1wjCj =
⎧⎪⎪⎪⎨⎪⎪⎪⎩
1 frequency of SNP j ≤ T
0 otherwise.
A limitation of VT is the reliance on functional information because methods used
to determine the functionality of variants have been shown to have a high error rate.
RareCover
RareCover by Bhatia et al. (2010) is a model-free method that attempts to select the
subset of variants that has the greatest correlation with the phenotype of interest in
a fixed window. RareCover utilizes forward variable selection by including only the
most discriminating variants into the subset. The discriminating power of the subset
is measured by the ability of the selected variants to differentiate between cases and
controls. To avoid the computational demand of checking all possible subsets, a greedy
algorithm is used to find the most discriminating variant group that maximizes the
test statistic over all variants in region [9].
RareCover Steps:
Suppose that a window is defined on a subset C selected from a group of S variants
and a super variant AC (called the union-variant) is constructed as:
AC = ⎧⎪⎪⎪⎨⎪⎪⎪⎩
1, if and only if IC > 0
0, otherwise.
where IC = ∑
k∈SGk. For the different variant subsets, the correlation between the
disease status and the union-variant AC is computed and denoted by CORR(AC ,D).
The RareCover test statistic is the maximum correlation between the disease status
19
and all possible union-variant constructs:
CORR(S,D) = max
C⊆S CORR(AC ,D).
Significance is assessed as the fraction of the permuted samples whose CORR value
matches or exceeds t. A stopping rule is put in place once two test statistics no
longer exceed a pre-specified threshold τ . RareCover is computationally expensive.
However, the greedy algorithm introduced reduces the required computations from∼ n2∣S∣ to ∼ ∣S∣n [9].
Rare Variant Test (RVT)
The RVT by Morris and Zeggini (2010) is an extension of CAST and CMC for quan-
titative traits (QTs). The QT is modeled under a linear regression framework where
rare variants are aggregated by gene and the QT is then regressed with an indicator
function or as the proportion of rare variants an individual carries. The QT is as-
sumed to be N(µ,σ2) distributed and the test of association is carried out using a
Likelihood Ratio Test (LRT) [67].
To carry out RVT:
Let ngi be the number of rare variants in the ith individual and rgi the variants for
which at least one copy of the minor allele is carried. When the QT is modeled as
a function of the proportion of rare variants carried, then E(yi) = α + λ rini + βxi.
When the phenotype is modeled as a function of the presence of a rare variant, then
E(yi) = α + λIj(i) + βxi. In both models λ can be interpreted as the expected in-
crease for carrying at least one minor alleles in an affected individual relative to an
unaffected individual.
One of the strengths of RVT is that it can easily be extended to case-control studies
and covariates can be included in the model. However, as pointed out by the authors,
to attain power, variants with a MAF between 1% and 5% must be included [67].
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Kernel-based Adaptive Cluster (KBAC)
The KBAC of Liu and Leal (2010) is a method that combines variant classification
and association testing under a unified framework. KBAC models an individual’s
disease risk as a mixture with two components for causal and non-causal variants.
Instead of using each variant individually, KBAC uses continuous adaptive weighting
of the multi-site genotypes and selects the weights based on the kernel of the known
non-causal variant component. KBAC was specifically designed to deal with variant
misclassification and allows for interactions [56].
KBAC implementation:
For the multi-site genotype Gj, the risk is denoted by Rj = n1jnj where n1j represents the
number of affected (1) individuals and nj the combined total of affected and unaffected
individuals. Rj, with probability pij, can be modeled as a mixture distribution with
two components based on the kernels κj:
Rj
D∼ pii non-causalucurlyleftudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymoducurlymidudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymoducurlyrightκ0j(Rj) +(1 − pij)
causalucurlyleftudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymoducurlymidudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymodudcurlymoducurlyright
κAj (Rj) .
It is assumed that κ0j(Rj) is known when the multi-site genotype Gj is non-causal
and κAj (Rj) is unknown for causal Gj. The kernel for the known component, κ0j(●)
is used to adaptively weigh each of the multi-site genotypes.
To determine the individual weight of each variant, the kernel of the known component
can be integrated out as:
wj = ∫ Rˆ0j
0
κ0jdr =K0j (Rˆj).
These weights can then be assigned to those individual who have the Gj genotype.
The one-sided KBAC statistic is given by:
m∑
j=1 (n
1
j
n1
− n1j
n0
)K0j (Rˆi).
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This one-sided test can be interpreted as testing for enrichment of causal variants
in affected individuals. KBAC can be implemented for two-sided tests when it is of
interest to test for frequency differences in affected and unaffected individuals as:
( m∑
j=1 (n
1
j
n1
− n0j
n0
)K0j (Rˆj) )2 .
The advantages of the KBAC are that it allows for covariates and interactions to be
considered and it is robust to the inclusion of non-causal variants [56]. The major
disadvantage of the KBAC is that it requires empirical computation of significance.
2.3.2 Directional Tests
Tests in this category allow for protective and risk variants to be analyzed jointly. This
type of tests are of particular importance because there are instances in which a gene
contains variants that can have opposite effects on the trait of interest. An example of
a gene with bi-directional effects is gene PCSK9 and LDL-C, where different variants
in this gene can lead to either elevated or decreased LDL-C [19].
The adaptive Sum test (aSum)
The aSum test by Han and Pan (2010) extends the Sum test for common variants by
Wang and Elston (2007) to include both common and rare variants. aSum was created
for case-control designs and is implemented in a marginal regression framework where
the variants are coded in a data-adaptive manner. The aSum attempts to reduce the
multiple testing burden by combining the effects of several variants into a single
common coefficient [33].
Implementation Steps of aSum
To select SNPs by allele frequency, a pre-selected cut-off, α0, is used. Then:
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1. Fit the marginal regression model for each SNP j: Logit Pr(Di = 1) = β0 +
m∑
j=1Gijβj obtaining βˆM,j and p-value pM,j.
2. For SNPs that satisfy βˆM,j < 0 and pM,j ≤ α0, the SNP codings, G⋅j, are changed
to G∗⋅j = 2 −G⋅j.
3. Fit the common-effect model
Logit Pr(Di = 1) = βc0 + m∑
j=1Gijβc.
The score statistic U and it’s covariance V are calculated as:
U⃗ = m∑
i=1(Di − D¯)Gj, V = D¯(1 − D¯) m∑i=1(Gj − G¯)(Gj − G¯)′
where D¯ =
m∑
j=1Dj
m and G¯ =
m∑
j=1Gj
m .
4. Permute the original data B times. For each permuted data {(D(b)i ,Gi)}, repeat
steps 1-3 to obtain the null score statistic U (b).
5. Calculate the sample mean and sample variance of U (1), . . . , U (B) as U0 and V0.
The aSum test statistic is:
aSum = (U −U0)V −10 (U −U0).
The p-value of the test can be obtained by matching the moments of the null distribu-
tion to those of the empirical distribution . Alternatively, the p-value can be obtained
using permutation. The aSum can be constructed in a way that rare and common
variants each have their own group and a two-degree of freedom tests is constructed
similarly as done in the common-effect model [33].
A drawback of aSum is the that the test is based on the assumption that the SNPs are
in in LD, which may not hold since rare variants are often not in LD. aSum is prone
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to lose power for large values of α0. In addition, the theoretical null distribution is
only an approximation, thus permutation may be necessary. While the type I error
can be controlled when permutation is used, this can be computationally intensive.
C-alpha (C-α)
The C-α by Neale et al. (2011) is an extension of a test for overdispersion developed
by Neyman and Scott (1966). Neale et al. (2011) apply this test to assess the
difference in variants observed in cases versus controls. Overdispersion is assessed by
the difference in variant copies in cases and controls rather than differences at the
individual level. In addition, this new C − α was specifically developed to allow for
the mixture of variants with opposing effects [69].
Implementation of C − α:
When a total of nj individuals carries variant j, if we assume that the variant carrier
count in cases (n0j) has a binomial distribution with common probability p0, the test
statistic T under the null can be computed as:
T = m∑
j=1 [(n0j − njp0)2 − njp0(1 − p0)]
with variance
V ar(T ) = c = maxn∑
n=2 m(n) n∑u=0 [(u − np0)2 − np0(1 − p0)]2f(u∣n, p0).
where m(n) is the number of variants with n copies and f(u∣nj, p0) represents the
probability of observing u copies at the jth variant.
Under the null hypothesis, T ∼ N(0,1). Since it is possible that there is an excess
observation of singletons (i.e., variants seen only once), these are grouped together
as a single observation. C-α can also accommodate different sampling designs by
incorporating weights wj into the test statistic as:
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T = m∑
j=1w−1j [(n0j − njp0)2 − njp0(1 − p0)].
The C-α test is sensitive to non-causal variants. However, to circumvent a drop in
power, the test could be implemented using the weighted version [69].
Wu et al. (2011) introduced the Sequence Kernel Association Test (SKAT) as a
generalization of C−α for QTs using weights based on the sample variant frequencies.
SKAT can also be implemented as Madsen and Browning’s WSS by using variant
frequency weights [102]. Recently, Lee et al. (2012) presented a correlation-based
weighted version of SKAT and burden tests for dichotomous traits [52].
The Replication-based test (RBT)
The RBT by Ionita-Laza et al. (2011) was created to allow for the inclusion of variants
with opposing direction into a weighted sum-like statistic. The RBT proposes a
negative log-based weight for the probability that groups have some number of minor
allele counts observed in cases and controls. This probability is then calculated based
on a Poisson distribution. RBT is implemented under a case-control setting with an
equal number of cases and controls [39].
Implementation:
Let nk
′
k denote the number of individuals in a group that have cases with k
′ copies
and controls with k copies of some variant and assign a weight wk
′
k to such a group.
Then the a weighted sum-statistics can be constructed as
S = Nr∑
k=0 ∑k′>knk′k wk′k
where Nr is the maximum number of times that a variant is observed in controls.
When the number of copies in cases exceeds those observed in controls, Ionita-Laza
et al. (2011) proposed data-dependent weights:
wk
′
k = − log[p(k, k′)] for k′ > k.
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With the new weights incorporated in to the WSS, the RBT test statistic is denoted
as follows:
S = Nr∑
k=0 ∑k′>k−nk′k log[p(k, k′)], (S+ for risk variants).
Assuming that the variant count follows a Poisson distribution, the probability of
observing k′ variants in cases and k in controls, can be calculated using the Poisson
CDF (ppois) as:
p(k, k′) = ppois(k, fˆ) ⋅ (1 − ppois(k′ − 1, fˆ)), where fˆ = k + k′
2
.
A two-sided test can be implemented by taking the maximum of the statistics S+ and
S−, max(S+, S−), where S− is the statistic for protective variants. To test for both risk
and protective effects, a test statistic can be constructed as the sum of the one-sided
test statistics:
SC = S+ + S−.
Information about the probability that a variant is functional, denoted by p(j), can
be incorporated into the test statistic as follows:
S = Nr∑
k=0 ∑k′>k ∑j∈(k,k′)−p(j) log[p(k, k′)].
When p(j) = 1 for all variants j, the regular statistic S is recovered [39]. RBT is a
robust test and suffers only a minor power loss for the directionally. Since a case-
control design is used, population structure needs to be properly controlled to avoid
an increase in false positives.
2.4 Methods for Selective Sampling
Because the genetic etiology of complex traits is much more difficult to decipher, cre-
ative ways to detect disease-causing genes have been presented. Several studies have
shown that for complex quantitative traits, individuals at the extreme of the trait
distribution tend to harbor rare variants. As a way to enrich samples to detect rare
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variants, individuals with extreme traits can be ascertained in what can be referred
to as selective sampling. The underling idea of selective sampling called “selective
genotyping” was discussed by Lander and Botstein (1989) in the context of selecting
the most informative animal crosses to detect Quantitative Trait Loci (QTLs) using
linkage analysis [50]. Lander and Botstein (1989) proposed reducing the number of
individuals genotyped by selecting individuals at the tails of the trait distribution
under the premise that these individuals would contribute the most linkage informa-
tion. They presented an approach to determine the contribution of individuals in the
extremes to the total linkage information. For example, they reported that ∼ 80% of
linkage information came from individuals beyond one standard deviation from the
mean [50].
Selective sampling can take several forms. The most common is the extreme trait
(two-tail) design where individuals at both extremes of the distribution are sampled
as in figure 2.3. Without loss of generality (WLOG), suppose that individuals with
a trait value beyond the upper threshold U are the affected. Individuals at the other
opposite extreme, i.e. individuals whose phenotype falls below the lower threshold
L, can serve as the comparison group. Recently, Edmond et al. (2012) combined
exome sequencing and extreme sampling of the age of onset of individuals susceptible
to lung infection and discovered missense rare variants in gene DCTN4 [23].
Alternatively, individuals from only one tail (as shown in figure 2.4) can be sampled
and the comparison can be sampled from the general population or an independent
cohort. In the following section, I present several methods that have incorporated the
idea of selective sampling.
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L µ U
Figure 2.3: Illustration of the Extreme-Trait/Two-Tail Design.
µ U
Figure 2.4: Illustration of the One-Tail Design.
Rare Variants found Exclusively (RVE)
The method based on Rare Variants found Exclusively (RVE) in cases versus con-
trols was described by Cohen et al. (2004) in the study of high-density lipoprotein
cholesterol (HDL-C). Note that RVE is more appropriately classified as a burden test
because it quantifies the variants found in either cases or controls. However, I have
listed RVE as a method for analyzing selected samples because it was first described
by Cohen et al. (2004) in the context of comparing variant counts in individuals in
the extremes.
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The RVE quantifies the difference in rare variants carried between individuals at the
upper and lower 5% of the HDL-C plasma distribution to mimic a case-control design
[17]. The excess of rare nonsynonymous variants in the extremes are contrasted and
tested by using Fisher’s exact test. By design, Fisher’s exact test is conservative.
In addition, dichotomizing the trait distribution and treating the upper and lower
extremes as a case-control design is discarding information which is known to be very
inefficient.
Likelihood-Based Approach Using Selective Sampling for QTLs
Huang and Lin (2007) introduced a likelihood-based approach for selective-genotype
designs of QTL under the premise that individuals in extremes are more likely to
carry disease-causing alleles. To account for trait-dependent sampling, they provide
two options to deal with the selective sampling: 1) Include the phenotype information
of all individuals sampled, but only include the genotype information of those in the
extremes or 2) Discard trait and genotype information for individuals who are not in
the selection region C. Depending on the design, the likelihood can be written in full
or conditional form [37].
Implementation:
Let P (Yi∣Gi, θ) denote the conditional density function, indexed by θ = (α,β, σ2)
WLOG, assume we have a single locus model:
Yi = α + βGGi + i, i ∼ N(0, σ2).
Let γ represent the multi-site genotype frequencies and let P (G;γ) denote the density
for the genotypes.
Two general selective-genotyping designs options
1. To account for selective sampling, the full likelihood includes the selection prob-
ability of all individuals. However, for individuals whose phenotype fall beyond
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the regions of interest, only their genotype is used in the selection probability:
n∏
i=1 P (Yi∣Gi; θ)P (Gi;γ) N∏i=n+1∑G P (Yi∣G; θ)P (G;γ).
2. When n individuals whose phenotype are below cL or above cU are selected for
genotyping, the conditional likelihood (using θ and γ) is written as:
n∏
i=1 P (Yi,Gi∣Yi ∈ C) = n∏i=1 P (Yi∣Gi; θ)P (Gi;γ)∑
G
P (Yi ∈ C∣G; θ)P (G;γ) .
Alternatively, the likelihood in terms of θ can be written as:
n∏
i=1 P (Yi, ∣Gi, Yi ∈ C) = n∏i=1 P (Yi∣Gi; θ)P (Yi ∈ C∣Gi; θ) .
To account for the selection of individuals with trait above a threshold U or below a
threshold L, P (Yi ∈ C∣Gi; θ) is calculated as:
P (Yi ∈ C∣Gi; θ) = 1 −Φ(U − α − βGGi
σ
) +Φ(L − α − βGGi
σ
).
The primary benefit of this likelihood-based approach is that it accounts for trait-
dependent sampling. Huang and Lin (2007) report that the power increases when
the thresholds become more extreme [37]. However, Lander and Botstein (1989)
cautioned that using individuals in the very extremes (say at the 1% extremes versus
5%) can result in spurious results as individuals in the tails may have a different trait
etiology [50].
Kryukov et al. (2009)
For resequencing data, Kryukov et al. (2009) presented a strategy based on collapsing
and using the extreme-trait design. For individuals who do not carry disease-causing
variants, the phenotype is assumed to follow a N(µ,σ) distribution. Individuals
carrying one or more disease-causing variant have a mean that is shifted by the
quantity δ. The trait distribution of these individuals is represented by N(µ + δ, σ).
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To select the thresholds, Kryukov et al. (2009) ranked individuals by their trait values
and proposed to take the upper and lower percentiles from this list. To test for rare
variant association, they used the CMC. To compare whether the carrier frequencies
under the null follow a 50%/50% ratio, they applied the chi-square test. In addition
to the test of rare variant carrier frequency, Kryukov et al. (2009) also compared the
carrier frequency of both rare and common variants. Rather than using the stringent
α = 5 × 10−8 significance level suggested for GWAS, they propose using exome-wide
significance based on 20,000 genes for α = 2.5 × 10−6 [46].
Almost-Extreme Sampling
Li et al. (2011) introduce the notion of “almost-extreme sampling” to make inference
more robust to heterogeneity in the extremes. Almost-extreme sampling requires
that two additional thresholds be introduced so that the very extreme tails of the
distribution are trimmed. The proposed sampling scheme is implemented using the
CMC. In addition to proposing almost-extreme sampling, Li et al. (2011) also showed
that implementing this design in conjunction with a two-stage designs is a cost-
effective strategy [54].
Implementation:
Assume that the trait has a N(µ,σ2) distribution and that Y can be represented as
Y = µ + ε where ε ∼ N(0, σ2). As before, L and U denote the thresholds for the qth
and (1 − q)th quantiles, respectively. By using the truncated normal from Johnson
& Kotz (1970), a regular extreme-trait design conditional on the genotype G can be
represented as:
f(Y ∣G, Y < L or Y > U) = N(µ,σ2)
1 −Φ(U−µσ ) +Φ(L−µσ ) .
To perform almost-extreme sampling, two additional thresholds are introduced such
that L1 < Y < L2 < µ and U1 < Y < U2 < µ as seen in figure 2.5.
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L1 L2 µ U1 U2
Figure 2.5: The Almost-Extreme Sampling Design.
The density is then modified to incorporate the new thresholds as [54]:
f(Y ∣G,L1 < Y < L2 or U1 < Y < U2) = N(µ,σ2)
Φ(L2−µσ ) − (L1−µσ ) +Φ(U2−µσ ) −Φ(U1−µσ ) .
A limitation of almost-extreme sampling is that usually the tails of a trait are enriched
with individuals with causal variants.
2.5 Gene Discovery Approaches for Mendelian Traits
Traditional Linkage
Genes responsible for Mendelian traits are traditionally analyzed using Linkage meth-
ods. Linkage analysis is based on the congregation of loci. There are many markers
with unknown function in the genome that are known and serve as a proxy. Anal-
ysis can be carried out under a model-based or distribution-free approach. Under
a model-based framework, knowledge of the disease model is required. The disease
model is made up of the mode of inheritance and the variant allele frequencies in
the population. For Mendelian diseases, the modes are dominant or recessive. The
model-based approach relies on the recombination fraction (θ), the probability that
two loci segregate together. Then by the LOD (i.e. Log ODDs) score method, the hy-
pothesis of no linkage between a marker and disease loci, H0 ∶ θ = 12 , is tested against
32
the alternative H1 ∶ θ < 12 and the LOD score is based on the log of the likelihood
ratio and for a single marker it is denoted as:
LOD(θ) = log10 L(θ)L(θ = 12) .
The general form of L(θ) for single-marker (i.e., two-point) linkage of Mendelian
traits is L(θ) = θr(1 − θ)n−r where n is the number of offspring and r is the number
of recombinants [79].
Distribution-free linkage does not require specification of the disease model and is
based on the frequency of shared alleles between relatives. For alleles that are the
same in a relative pair, say siblings, the alleles inherited by a common ancestor are
said to be Identical-by-Descent (IBD) or if they are the same but inherited from
different parents, alleles are said to be Identical-by-State (IBS). Under the null hy-
pothesis, siblings are expected to share 0, 1, or 2 alleles with probability 1/4, 1/2,
and 1/4, respectively. Under the alternative, we would observe a greater number of
pairs sharing 1 or 2 alleles IBD more frequently than expected. Testing of IBD carrier
frequencies can be carried out using a Chi-square test.
Linkage analysis is greatly limited by the need of family data. Many multi-generation
families are required yet many Mendelian diseases are extremely rare. For complex
traits, linkage-based methods perform poorly mostly because many traits do not
oblige to Mendelian rules of inheritance.
Recent Approaches
Filtering approach
An approach to find the causal variant in Mendelian traits has been the filtering ap-
proach. The filtering approach, as the name implies, is based on setting criteria to
reduce the list of variants from exome or whole genome sequencing to a list of candi-
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date variants. This filtering approach doesn’t have any formal statistical test, rather
it was initially described as a “proof-of-principle” approach for identifying the causal
variants in the exome. The filtering approach is based on a set of assumptions, the
first is that the majority of Mendelian traits result from variants in the protein-coding
regions of the gene. Other assumptions or information that can be used in filtering
include using SIFT or Poly-Phen scores to predict damaging variants, removing vari-
ants found in the exomes of unaffected family members, removing variants found in
public databases, etc. Ng et al. (2008) first discussed the possibility of using a fil-
tering approach on a single exome in which they limited their analysis to non-silent
variants and by successively using several filtering criteria managed to reduce a list of
over 12,000 variants to ∼ 1,500 variants that were more likely to be disease causing [72].
In figure 2.6, I present a diagram of the variant filtering pipeline incorporating sev-
eral filtering criteria that could be considered when producing a candidate gene list
as suggested by the examples presented as well as those suggested by Ku et al. (2011,
2012)[48, 47]. To demonstrate the utility of using filtering on the exome as a proof-
of-principle, Ng et al. (2009) compared the exomes of four individuals with the
Freeman-Sheldon syndrome and reported that the previously identified gene MYH3
was present in all exomes [75]. The following year, Ng et al. (2009) again used filtering
and reported a de novo missense variant in MLL2 as the cause of Kabuki syndrome
[73].
There have been filtering schemes that incorporate linkage information such as the
LOD score or Identity-By-Descent (IBD) sharing. Ro¨delsperger et al. (2011) present
a filtering algorithm based on the IBD sharing of relatives, in particular those who
share both alleles IBD. In addition to reducing the candidate gene list, their method
provides a quality control check to detect “sequencing errors” [90].
The filtering approach is not foolproof. One of the most common criticisms of filtering
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Figure 2.6: Diagram of the filtering pipeline for variant prioritization. Note that
several paths are possible in filtering out variants [72, 48, 47].
is the possibility of completely missing the disease-causing variants because of genetic
heterogeneity or that the causal variant went undetected in the public databases
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[6]. Ro¨delsperger et al. (2011) also caution against using Bioinformatics tools in
filtering since these often have a low sensitivity to detect causal variants, however
their approach can have an increased number of false positives when variants are in
linkage disequilibrium [90].
Joint-Rank Method
The joint-rank method by Ionita-Laza et al. (2011) was designed to combine the
weighed sum approach and filtering for gene discovery in Mendelian traits. This
method assigns a rank to each gene based on both the weighted sum and filter-based
approaches for different variant groupings. The variant groupings can be created
to include only novel variants, rare variants, variants filtered out using databases,
etc. The test statistic for the joint-rank method is based on tabulating the number
of affected individuals with one or more alleles in the variant in question (i.e. the
burden) [40].
Implementation:
Let MA denote the number of novel variant positions observed in a set (A) of se-
quenced affected individuals (1) at locus G. For each affected individual i, the load
Li of novel non-synonymous variants is calculated as:
Li = MA∑
j=1 1NS(j)Gij, where 1NS(i) =
⎧⎪⎪⎪⎨⎪⎪⎪⎩
1 NS variant
0 otherwise.
To rank genes, the filter-based statistic is introduced:
Sfilter = A∑
j=1 I{Li>0}.
The total number of rare variants carried in affected individuals for each variant site
j, denoted by T (j) is summed to form a new statistic, S:
S = M∑
j=1T (j).
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S can be modified to resemble a WSS-like statistic by including weights, wj:
Sw = M∑
j=1wjT (j).
Assuming that variant frequencies (fj) follow a Beta(α,β), then fj is estimated as:
fˆj = xj + α
n0 + α + β
where xj is the count of times the minor allele of variant j is seen in the unaffected
individuals and n0 is the total number of unaffected individuals.
The joint rank statistic is simply the average of the ranks from the weighted sum
statistic (Sw) and the filter-based statistic (Sfilter):
S = Rank(Sfilter) +Rank(Sw)
2
.
The benefit of the join-rank statistic is that it can be modified to include rare novel
variants or simply the filter-based variants. In addition, this method can be applied
to data based on families or unrelated individuals. A possible limitation is that
the density of the WSS is approximated, which may not be appropriate in practice
because of the small sample sizes expected for Mendelian trait studies.
2.6 Difficulties in the Quest for Rare Variants
Many of the difficulties in the detection and analysis of common variants translate to
rare variants. Population substructure, or when subpopulations have different allele
frequencies, can result in false positive if it goes uncorrected. For GWAS, principle
components can be effective for controlling population substructure. For rare vari-
ants, the concern of population substructure is attenuated by their extremely low
frequency, making population subdivision more likely. GWAS require very large sam-
ple sizes (in the hundred thousands) in order to detect common variants that have
small to moderate effect sizes. While rare variants tend to have greater effect sizes,
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many are de novo mutations and individual-specific. Recently, Nelson et al. (2012)
sequenced 202 genes in 14,000 individuals and reported that nearly three quarters of
rare variants were carried in one or two individuals [71].
To resolve some of the missing heritability, other types of genetic factors such as struc-
tural variants must be considered. Copy number variants (CNVs), a specific class of
structural variants, have already been reported to partially contribute to the dark
matter in diseases like Autism and Chron’s disease [100]. In addition, Gene-Gene
(GxG) and Gene-Environment (GxE) interactions may also be involved in the etiol-
ogy of disease. The difficulty in analyzing such interactions goes beyond developing
statistical methods; rather to make biological sense and draw plausible conclusions
from them.
Recently, a shift to understand the biology of diseases has lead back to Mendelian
traits. Understanding the etiology of Mendelian traits is far from simple. For exam-
ple, genetic heterogeneity at the locus level disrupts the one-to-one correspondence
expected in Mendelian diseases. This one-to-one correspondence can also be dis-
rupted by imprecise disease classification. Phenotypic heterogeneity as seen in HTG
and breast cancer subtypes makes robust phenotype definitions necessary. Programs
such as the NIH’s UDP have called for refined phenotype definitions given the ad-
vances in technology and the increased knowledge of biological mechanisms [28].
Methods implemented for rare variants are susceptible to variant misclassification.
Misclassification occurs when a variant is incorrectly defined as causal or when non-
causal variants are called causal and are included in the analysis. In this regard,
statistical methods that are robust to non-causal variants are needed. To improve
variant specification, functional analysis may be utilized to determine the variant
type (e.g., non-synonymous, indel, splice-site, etc.) as well as Bioinformatics tools
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(e.g., SIFT or Poly-Phen) that determine the potential of a variant to be damaging
or neutral. However, many of these tools have low sensitivity and have been reported
to be error-prone [26].
Current methods make use of collapsing to enrich the signal of rare variants. However,
doing so makes it difficult to discern the causal variant in a grouping. Variants with
opposite effects can be present at a locus, those that confer a protective effect and
those than increase the susceptibility to disease. Inclusion of both types of variants
can lead to a loss of power. In addition, some methods purposely exclude common
variants or assume that there is no LD between rare and common variants. Yet both
rare and common variants can reside on the same locus and are often jointly con-
tribute to a common disease [18]. Ideally, methods should be robust to the inclusion
of causal and non-causal variants and be able to discriminate between risk and pro-
tective variants without losing power.
Chapter 3
Selective Sampling in Rare Variant
Association Studies
The purpose of the current chapter is to evaluate the performance of several sampling
designs for rare variant-quantitative trait (QT) association studies. Practical issues
related to designing efficient studies, such as threshold selection and sample size, are
investigated using extensive simulations. The chapter is concluded with a discussion
of the findings and implications for future sequence-based studies.
3.1 Introduction
Understanding of diseases with complex etiologies have been greatly enhanced over
the past two decades. In particular, Genome-Wide Association Studies (GWAS) have
led to the identification of many common variants (with MAF ≤ 5%), some of which
have been disease-causing. Yet, much of the heritability in complex traits remains
to be explained [62] and many of the reported common variants have small effect on
the trait of interest. Consider height, for example. In one study, Allen et al. (2010)
reported that 180 SNPs were associated with human height but these variants collec-
tively explain only 10% of the variance in height [1]. To explain 45% of the variance
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in height, Yang et al. (2010) reported that close to 295,000 SNPs could be required
[104]. Because common variants typically do not contribute significantly to the her-
itability of complex traits, interest has shifted to uncommon variation driven by the
hypothesis that common complex traits may result from rare causative variants [31]
with greater effects. Specifically, rare variants have been shown to be associated with
a variety of complex traits, including colorectal adenomas, low density lipoprotein
cholesterol (LDL-C) and triglyceride (TGs) levels [17, 25, 43, 91]. The identifica-
tion of rare variants has been facilitated by advances in next-generation sequencing
technology [94]. However, sequencing the large number of genomes at high coverage
required for rare variant discovery is currently infeasible. In addition, the volume of
data generated from high throughput sequencing technologies poses great challenges
in both data processing and storage [84].
To reduce the sequencing cost for quantitative traits (QT), two strategies can be in-
corporated into the study design: sampling individuals with extreme trait values and
utilizing publically available phenotyped cohorts. In order to design a cost-effective
study that is adequately powered for rare variant discovery, a comprehensive eval-
uation of sampling strategies is imperative. To optimize power for a fixed sample
size, a frequently used study design is to select individuals with extreme quantitative
traits (QTs). This design has been used for genome-wide association studies [36, 51]
and was used in the Dallas Heart Study to implicate rare variants in a number of
metabolism-related traits [17, 91]. Extreme sampling is currently being used in ex-
ome sequencing studies including the NHLBI-Exome Sequencing Project (ESP). By
studying individuals with extreme QTs, this design decreases misclassification and
can enrich for causal variants. Sequencing individuals with extreme trait values has
also been shown to be a cost- and time-effective approach for the mapping of complex
quantitative traits [37, 51, 55].
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For many complex traits, identifying causal variants associated with only one tail of
the QT distribution is often of interest when the extreme QT has clinical relevance.
For example, studying the genetic etiology of obesity and hypertension may be of in-
terest. For the study of obesity where BMI is the quantitative trait of interest, often
individuals with normal BMI are used as a comparison group instead of individuals
with extremely low BMIs. While extremely low BMIs can be caused co-morbidities,
the genetic architecture in genes of interest for BMI may be different in lean individ-
uals than those within the clinically normal limits. For hypertension, normotensives
are used as the comparison group since it is believed that those genes that modulate
systolic and diastolic blood pressure in the low extremes [41] may be different from
those that lead to increase these measures to a level of clinical significance.
Plomin et al. (2009) has suggested that a quantitative framework can be adapted in
mapping binary or continuous complex traits [85]. Incorporating the idea of extreme-
trait sampling for quantitative traits, Huang and Lin (2007) proposed a likelihood-
based method that accounts for selective sampling [37] in association studies with
common variants. For binary disorders, a liability threshold model can be applied
where polygenic and environmental factors form a latent variable [24]. Under this
model, individuals who have a liability above some threshold value exhibit the disor-
der while those whose liability falls below the threshold do not. In clinical practice,
QTs are often dichotomized. However, it is recommended that the full QT data be
used to avoid discarding information.
The purpose of this work is to determine the optimal sampling design for detecting
rare variant associations under a quantitative framework. This framework is based
on a general likelihood method for rare variant-complex trait association [55] that ac-
counts for selective sampling as done for common variants by Huang and Lin (2007)
[37]. By considering several factors influencing the study, the power and false positive
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rate for several selective sampling schemes are evaluated using extensive simulations.
For a fixed sample size, designs that use selective sampling may result in increased
power compared to population-based study designs where individuals are randomly
sampled from the general population. Options to increase the pool of individuals
available include using a less stringent cut-off or sampling individuals from the gen-
eral population for the comparison group. Another alternative is to sample individuals
from an existing public cohort where genotype and several phenotypes have been well
characterized. By using the distribution quantiles to determine selection thresholds,
asymmetric thresholds and unbalanced designs were compared to the symmetric bal-
anced sampling design. In addition, the percentage/proportion of causal variants (i.e.,
potentially disease-causing), among all variants was varied to include the range from
no variants being causal to all variants being causal. Remaining variants were neutral
variants having no effect on the trait. For variants that were causal, the variant effect
size (i.e., the mean shift induced by the variant) was varied and evaluated for the
designs considered. Note that for neutral variants, the variant effect size would be
set to zero. Finally, we explored the effect of dichotomizing the QT on power and the
value of incorporating data from existing cohorts.
3.2 Methods
Suppose that the number of rare variants for individual i (i = 1,2, . . . , n) at variant
site j (j = 1,2, . . . , l) is denoted by vij where vij = {0,1,2}. Note the vij represents
the genotype of an individual, for example, vij = 2 indicates that individual i is
homozygous (for the minor allele) at variant site j. Similarly, a new variable gij can
indicate whether an individual i carries at least one rare variant at site j, namely:
gij = ⎧⎪⎪⎪⎨⎪⎪⎪⎩
1, if vij = 1 or vij = 2
0, otherwise.
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Customarily, rare variants are aggregated, say at the gene locus, since their low
frequency would make it difficult to detect associations with individual variants. Thus
one can group or “collapse” multi-site genotypes into m groups. We let the groups
be indexed by k (k = 1,2, . . . ,m), presumably with m ≤ l. We define the collapsed
genotype Gik, similarly to what Basu and Pan (2011) call a “Super-Variant” [8], using
the CMC collapsing scheme from Li and Leal (2008) [53] as:
Gik = ⎧⎪⎪⎪⎪⎨⎪⎪⎪⎪⎩
1, if ∑
j
gkij > 0
0, otherwise.
In words, Gik serves as an indicator function of whether any rare variant is present
at any of the j variant sites in group k for individual i.
Let Yi denote the QT for individual i. For i ≠ j, assume that Corr(Yi, Yj) = 0 for
individuals i and j. Then Yi is modeled in a traditional regression framework using
the collapsed genotypes Gik:
Yi = β0 +∑
k
βkGik + εi, with ε i.i.d∼ N(0, σ2).
The βk coefficients represent the effect size of the collapsed genotypes Gik. Note that
this representation can be easily extended to include covariates like gender, age, race,
etc. In order to assess QT-rare variant association, a likelihood ratio test was chosen
for the type I error and power calculations.
3.2.1 Sampling Framework
WLOG, the indices will be dropped for simplicity. Following Huang and Lin (2007), to
implement a selective sampling scheme [37], we first let the selection region be denoted
by S such that if y ∈ S, then the individual is sampled. For example, suppose that for
a certain trait, all trait information on the population is represented by P = (−∞,∞)
and that S represents a subset (i.e,. S ⊆ P ) of individuals whose phenotype is greater
44
than some threshold T , so that S = (T,∞). Then for an individual with phenotype
Y , we define the selection indicator IS as:
IS = ⎧⎪⎪⎪⎨⎪⎪⎪⎩
1, y ∈ S
0, otherwise.
Since individuals are selected based on their phenotypic information, selection is
conditionally independent of their genetic information, thus the probability that an
individual is selected, i.e., whose phenotype falls in the selection region S, can be
expressed as:
P (IS = 1∣Y,G) = P (IS = 1∣Y ).
In order to account for the selective nature of the sampling scheme, the likelihood is
modified by conditioning on whether an individual’s phenotype falls in the selection
region, and thus IS = 1. Note that the likelihood under a random sampling scheme is
not equivalent to the likelihood that accounts for selection, P (Y ∣IS = 1,G) ≠ P (Y ∣G).
Thus the Selection-Corrected Likelihood is presented as:
P (Y ∣IS = 1,G) = P (IS = 1∣Y )P (Y ∣G)∫
y∈SP (IS = 1∣Y )P (Y ∣G)dy .
Depending on the approach taken to select individuals, the selection region and the
selection probabilities will change. In the next section, the sampling designs imple-
mented in this thesis are defined and the corresponding selection probabilities are
expressed, as needed.
3.2.2 Description of Study Designs and Sample Selection
For study designs involving quantitative traits, distribution-based thresholds are usu-
ally used to define the individuals who are of clinical interest. Without loss of gener-
ality, suppose the upper extreme of the QT distribution is the tail of clinical interest.
Individuals from the opposite extreme could serve as the comparison group. This type
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of design is the extreme trait design or a two-tail design [105]. Individuals from the
opposite extreme of the trait distribution are sometimes referred to as the “hypernor-
mal” control group [64] or “super controls” [85]. A second design is the one-tail design
where individuals with values at one extreme of the trait distribution are sampled
and compared to individuals sampled from the remainder of the distribution. With a
one-tail sampling design, a single threshold is specified to mark off which individuals
belong to the tail of clinical interest. Another alternative is to sequence only individ-
uals in one tail and select individuals randomly from the general population for the
comparison group. The sampling designs implemented in this thesis are summarized
in table 3.1 and displayed in figures 3.1(a)-(c).
Design 1: Extreme
Trait/Two-Tail
(Figure 3.1(a))
Design where individuals from both extremes are sampled,
i.e., two thresholds are used to mark off the upper and lower
extremes of the trait distribution.
Design 2: Single
Threshold/One-
Tail (Figure 3.1(b))
Design in which individuals with values at one extreme of the
trait distribution are sampled and compared to the individuals
from the remainder of the distribution.
Design 3: Single
Threshold and
Random Sample
(Figure 3.1(c))
One-tail sampling with the comparison group taken from the
general population; In this design, a single thresholds is used
to select individuals from the tail of clinical interest and the
comparison group is taken to be a random sample from the
general population or an existing cohort.
Balanced A design in which the number of individuals selected from the
tail of clinical interest and the comparison group are equal.
Table 3.1: Description of sampling designs.
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YL µ YU
(a) Design 1: Extreme Trait Design
µ YL = YU
(b) Design 2: One-tail Design
µ YU
(c) Design 3: One-Tail Design with Random Sample
Figure 3.1: Illustration of Three Sampling Designs.
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Within each of these designs, balanced and unbalanced designs are explored. In the
balanced design, the number of individuals sequenced from the tail of clinical inter-
est and the comparison group are equal. In the unbalanced design, the number of
individuals sequenced from each tail is not equal. We use sampling ratios such as a
1:2 ratio, where one individual from the tail of clinical interest is sampled per two
individuals from the comparison group. Within each of these sampling frameworks,
we further explore the effect of asymmetric thresholds on the power to detect rare
variant associations. When an exisiting cohort is used, asymmetric thresholds may
affect whether a design is balanced or not.
Returning to the representation of the selection region S and the selection probabil-
ity discussed in the previous section, new notation is introduced. In order to sample
individuals under a selective sampling design, say the extreme trait design (see fig-
ure 3.1(a)), a lower (Y L) and upper (Y U) threshold based on the quantiles (q) of the
trait distribution are defined as Y L = Φ−1(qL) and Y U = Φ−1(qU), respectively. Note
that for the extreme trait design, individuals with QT Y satisfying Y < Y L or Y > Y U
are included in the sample and thus the selection region is represented as:
S = {(−∞, Y L) ∪ (Y U ,∞).
The selection probability in this case would be represented as:
P (IS ∣Y = y)∝
⎧⎪⎪⎪⎪⎪⎪⎨⎪⎪⎪⎪⎪⎪⎩
Φ(Y L), Y < Y L
0, Y L < Y < Y U
1 −Φ(Y U), Y > Y U .
For simplicity the normalizing constant, Φ(Y L) + 1 − Φ(Y U), is not included in the
selection probability above for the extreme trait design. Note that for the one-tail
design, the probability of selecting individuals for either the tail of clinical interest or
the comparison group can be determined directly from the cdf, without the need of
a normalizing constant, since there is only one threshold.
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A symmetric extreme trait design can be implemented when the upper q and lower
1−q quantiles are used to define the thresholds for selecting individuals. For example,
Y U = Φ−1(0.95) and Y L = Φ−1(0.05) means that individuals with traits in the upper
and lower 5% of the distribution will be sampled. Note that the one-tail design
consists of selecting a single threshold such that Y U = Y L.
3.2.3 Approach for Analyzing Dichotomized Phenotypes
The quantitative approach is compared with the approach where the QT is analyzed
as a dichotomized trait (represented by D). In this case, D = 1 if Y ∈ S or D = 0
otherwise. For a single covariate, we can define pi = P (D = 1∣X). When several
covariates are of interest, pi can be similarly defined and we can use logistic regression
model such as:
log
⎛⎝ pi1 − pi⎞⎠ = β0 +∑j βjXj + ε.
Alternatively, when the association can be represented by a contingency table, chi-
squared or Fisher’s exact test can be used. Here, Fisher’s exact test is implemented.
3.3 Simulation Set-Up
Table 3.2 lists the information on the simulated data, which is based on African
Ancestry. Details on how the genetic data was generated can be found elsewhere [55].
Gene Length (bp) 1,500 bp
Mutation Rate 1.8 × 10−8/generation
Model for s Gamma(0.184,8,200)
Table 3.2: Settings for simulated rare variant data based on Africans [11].
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Briefly, the simulated genetic data was based the work of Boyko et al. (2008) who
use specific population genetics measures such as selection and demographic events
to model mutation distributions [11]. Specifically, the selection disadvantage (s) for
Africans was modeled using a Gamma distribution with parameters αA = 0.184 and
βA = 8,200. In the current work, only NS variants are considered since these are more
likely to be disease-causing or to affect protein function [87]. Furthermore, the set of
causal variants is denoted by C and is integrated into the phenotype distribution as
N(∑
k∈C βkGik, σ2). All variant sites within a gene region are analyzed but only variants
with a minor allele frequency of ≤ 0.01 are considered to be causal. 25, 50, 75 or 100
percent of the variant sites are randomly selected to be causal and affect the QT dis-
tribution while the remaining variant sites are set to be neutral. Note that the mean
is shifted by t standard deviations when the variant is causal: β˜ = tσ. For simplicity,
all variant groups were assumed to have the same variant effect. For the phenotypes
generated, different variant effects were used, namely t = {0.25,0.5,1.0,1.5}.
The sample sizes selected ranged between 1,000 to 10,000 individuals for each type
of design. The thresholds used for the tail of clinical interest were based on the
quantiles 0.90 or 0.95. For the extreme trait design, cut-offs of 0.05 and 0.10 were
used. When asymmetric thresholds were used, the cut-offs for the comparison group
ranged between 0.05 to 0.80 with increments of 0.05 or 0.10. For the one-tail design,
the quantiles selected were 0.90 and 0.95. When sampling individuals from the general
population for the comparison group, the quantile 1.00 is used to specify that the
individual is not selected based on their trait value. The existing cohort was simulated
with a size of N=10,000 individuals. To evaluate power, 10,000 replicates were used
using exome-wide significance α = 2.5X10−6. From here on, QT denotes quantiative
trait and DT denotes dichotomized trait.
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3.4 Results
3.4.1 Evaluation of Type I Error
The type I errors were evaluated for the three types of designs described in table 3.1
and illustrated in figures 3.1(a)-(c). For α = 0.05 and α = 0.001, the design parameters
were varied from changing the upper and lower thresholds, using unbalanced sampling,
and using asymmetric thresholds.
Type I Error Rates
Design Description qL DT QT
1 Extreme-Trait Design 0.05 0.0395 0.0521
2 Single-Threshold 0.95 0.0353 0.0514
3 One-Tail and Random Sample1 1.00 0.0398 0.0505
Table 3.3: Comparison of type I error for the three designs when the upper threshold
is set at qU = 0.95, balanced sampling is implemented in which 1,000 individuals are
selected from each extreme, and α = 0.05.
Type I Error Rates
Total Sampled No. Upper No. Lower qL DT QT
1000 500 500 0.05 0.0345 0.0528
1500 500 1000 0.10 0.0403 0.0545
2000 500 1500 0.15 0.0362 0.0519
Table 3.4: Comparison of Type I Error for unbalanced sampling from an existing
cohort with upper threshold qU = 0.95 and α = 0.05
Based on the simulations under several scenarios and designs, there is no significant
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Type I Error Rates
α = 0.05 α = 0.001
No. Upper No. Lower qU qL DT QT DT QT
100 900 0.99 0.09 0.0293 0.0537 0.0005 0.0012
200 800 0.98 0.08 0.0331 0.0530 0.0006 0.0011
300 700 0.97 0.07 0.0319 0.0529 0.0010 0.0016
400 600 0.96 0.06 0.0334 0.0583 0.0004 0.0010
500 500 0.95 0.05 0.0345 0.0528 0.0004 0.0018
600 400 0.94 0.04 0.0343 0.0539 0.0009 0.0015
700 300 0.93 0.03 0.0297 0.0566 0.0004 0.0012
800 200 0.92 0.02 0.0277 0.0542 0.0002 0.0010
900 100 0.91 0.01 0.0173 0.0552 0.0000 0.0014
Table 3.5: Comparison of Type I Error for α = {0.05,0.001} for varying thresholds
and unbalanced sampling from an existing cohort of fixed size N = 10,000. A total
of n = 1,000 individuals selected. Because an exisiting cohort is used, the thresholds
depend on the number selected from each tail. For example, when selecting 100
individuals from the upper tail and 900 for the lower tail, qL = 1 − 10010,000 = 0.99 and
qL = 90010,000 = 0.09, respectively.
discrepancies in the type I errors. When the QT is dichotomized, the type I errors
are below the specified significance level α. For example in the case when balanced
designs are implemented for α = 0.05, the type I errors are between 0.035 and 0.04 for
the dichotomized trait. This is because Fisher’s exact test was used and this approach
is known to be conservative.
3.4.2 Effect of β and Percent Causal Variants on Power
Figure 3.2 presents the power analysis for the three designs described in table 1 with
varying values of β and percent causal variants. Two thousand individuals were
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selected for sequencing from the general population, 1,000 from each extreme. The
upper threshold was based on the theoretical distribution at the 95th percentile,
Y U = Φ−1(0.95).
Figure 3.2: Power Comparison for Balanced Extreme Trait Design (Design 1), i.e.,
1000 individuals from upper and 1000 from lower tails. qU = 95% and qL = 5%,
β˜ = {0.25,0.5,1.0,1.5}.
When the variant effect size is β=0.25, design 2 and design 3 have negligible power
over the entire range of percent causal variants while for design 1 there is a modest
increase in power when at least 50% of the variants are causal. For an effect size
β=0.5 and greater, the power for design 2 significantly increases as the percent of
causal variants increases. Design 1 offers a power advantage over design 2 when the
variant effect is β=0.5, but when β={1.0,1.5} the power differences are minimal.
For example, when 25% of the variants are causal and β =1.5, the power for design
1 is 0.5495 and for design 2 it is 0.5447. Design 1 is robust to dichotomizing for
different values of β and percent causal variants. Designs 2 and 3 are sensitive to
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Figure 3.3: Power Comparison for Balanced One-tail (Design 2), i.e., 1000 individuals
from upper and 1000 from lower tails. qU = qL = 5%, β˜ = {0.25,0.5,1.0,1.5}.
Figure 3.4: Power comparison of one-tail design with a random sample (Design 3),
with 1000 individuals from upper tail at q = 95% and 1000 individuals from the
general population, β˜ = {0.25,0.5,1.0,1.5}.
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dichotomizing and the departure between the power of the QT and dichotomized
trait begins to increase as the percent of causal variants increases (see figure 3.1).
3.4.3 Effect of Sample Size and Threshold on Power
When an existing cohort is available, it is possible to implement an extreme trait
design under a varied range of values for β and percent causal variants. In panel
(a) of figure 3.5, 500 individuals were selected from each extreme with thresholds
Y U = Φ−1(0.95) and Y L = Φ−1(0.05). In panel (b), 1,000 individuals from each extreme
were selected for sequencing using upper and lower thresholds set to Y U = Φ−1(0.90)
and Y L = Φ−1(0.10).
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Figure 3.5: Power Plots for an Existing Cohort for (a) Φ−1(0.95) and (b) Φ−1(0.90).
A less stringent threshold with more individuals selected leads an increase in power.
For example, when β=0.5 and 75% of the variants are causal, the power for analyz-
ing the trait as quantitative is 0.3958 when the thresholds are Y U = Φ−1(0.95) and
Y L = Φ−1(0.05) and 0.5818 for thresholds Y U = Φ−1(0.90) and Y L = Φ−1(0.10).
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As opposed to the scenario when a fixed number of individuals are to be sequenced,
say 1,000 individuals from an existing cohort, in figure 3.6 I explore the gain in power
if the number of individuals sequenced from the cohort increases. The percent of
causal variants was set to 50%.
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Figure 3.6: Power Plots for an Existing Cohort with 50% Causal Variants for β˜ ={0.5,1.0} under a Balanced Design.
In the case were a balanced design is used, sampling more than 4,000 individuals
from an existing cohort of 10,000 does not lead to a significant gain of power when
β=0.5 or β=1. Specifically, for β = 1, increasing the number of individuals sequenced
from 3,000 to 4,000 increases power to 0.7331 from 0.7232. As more individuals are
selected from the entire cohort, the power begins to drop off for the dichotomized
trait. For example, when β=0.5 and a 5,000 individuals are sequenced, the power is
0.3438 compared to 0.3197 when 8,000 individuals are selected.
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3.4.4 Effect of Asymmetric Thresholds and Unbalanced Sam-
pling on Power
In figure 3.7, power is evaluated for the three designs under the sampling ratios of
{1:1,1:2,1:3,1:4} when β=0.5 and 50% of the variants are causal. 1,000 individuals
were sequenced from the upper tail using threshold Y U = Φ−1(.95).
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Figure 3.7: Power Comparison of Three Designs for Sampling Ratios 1:1, 1:2, 1:3,
and 1:4. Power for the QT is represented by a solid line and for the DT by a dashed
line.
Under the three designs, increasing the number of individuals sequenced in the com-
parison group from 1,000 to 2,000 (1:2 sampling ratio) leads to an increase in power.
Under the 1:1 sampling ratio for the QT, the power is 0.384, 0.172 and 0.163 for
designs 1, 2 and 3, respectively. Under the 1:2 sampling ratio, the power increases to
0.504, 0.296 and 0.296 for designs 1, 2 and 3, respectively. For design 1, there is a
modest increase in power for the 1:3 and 1:4 sampling ratios, while for design 2 and 3
power is greater (figure 3.7). When the QT is dichotomized, there is a trivial power
loss for design 1, but there is a marked drop in power for both design 2 and design
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3. For example, in design 2 under a 1:3 sampling ratio the power is 0.380 for the QT
and 0.196 for the dichotomized trait.
In table 3.6, sampling ratios up to 1:3 are evaluated in an existing cohort for several
values of β and a greater range of percent causal variants. For an existing cohort of
10,000, selecting 500 individuals from each tail from the upper and lower 5 percentiles
constitutes the 1:1 sampling ratio. Sequencing 1,000 (1:2) and 1,500 (1:3) individ-
uals from the lower tail correspond to the 10th and 15th percentile of the distribution.
Sampling Percent Causal Variants
Ratio β˜ 25% 50% 75% 100%
1:1 0.25 0.0004/0.0004 0.0034/0.0039 0.0162/0.0195 0.0562/0.0672
0.5 0.0183/0.0215 0.1238/0.1444 0.3591/0.3958 0.6692/0.7140
1 0.2031/0.2348 0.5770/0.6267 0.8381/0.8682 0.9769/0.9889
1:2 0.25 0.0004/0.0005 0.0079/0.0079 0.0371/0.0393 0.1174/0.1275
0.5 0.0417/0.0436 0.2179/0.2303 0.5117/0.5332 0.8032/0.8240
1 0.2834/0.3022 0.6691/0.6901 0.8917/0.9069 0.9955/0.9974
1:3 0.25 0.0011/0.0014 0.0097/0.0103 0.0445/0.0481 0.1404/0.1510
0.5 0.0536/0.0555 0.2430/0.2569 0.5437/0.5646 0.8371/0.8574
1 0.3171/0.3252 0.6925/0.7083 0.9149/0.9250 0.9977/0.9990
Table 3.6: Table of Effect of β˜ and percent causal variants in an unbalanced design
(based on sampling ratios) when sampling from an existing cohort. The upper thresh-
old was set to Y U = Φ−1(0.95). For the 1:1 sampling ratio, 500 individuals sequenced
from upper extreme and 500 from the lower where Y L = Φ−1(0.05). Similarly for the
1:2 and 1:3 sampling ratios, 1,000 and 1,500 were sequenced from the lower threshold
of Y L = Φ−1(0.10) and Y L = Φ−1(0.15), respectively. Power reported as DT/QT.
For β=0.25, increasing the sampling ratio leads to a modest increase in power even
if 100% of the variants are causal. When β = {0.5,1}, there is a minor gain in power
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when the sampling ratio is 1:2. The power gain between the 1:2 and 1:3 sampling
designs is modest. For example, when β=1 with 50% causal variants for the QT, the
power is 0.6901 and 0.7083 for the 1:2 and 1:3 sampling ratios, respectively. Increas-
ing the sampling ratio from 1:1 to 1:2 has a greater impact on power for an effect
size of β=0.5 and when at least 75% of the variants are causal. When β=1 and 100%
of the variants are causal, a 1:1 sampling ratio is sufficient to achieve power greater
than 0.97.
In figure 3.8, power is evaluated when 1,000 individuals are available for sequencing
from an existing cohort where the thresholds are not necessarily symmetric nor the
design balanced. The interest here is to note whether power increases as the number
individuals sampled from upper extreme increases.
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Figure 3.8: Evaluation of the effects of asymmetric thresholds and unbalanced sam-
pling on power for a fixed sample of 1,000 from an existing cohort. The percentage
of causal variants ranges between 25% to 100%.
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When the percent of causal variants is greater than 50%, power is maximum when 400
individuals are sequenced from the upper extreme Y U = Φ−1(0.96) and 600 from the
lower extreme Y L = Φ−1(0.06). Specifically when 75% of the variants set as causal,
power is 0.4113 for the QT and 0.3821 for the dichotomized trait. It is interesting to
note that power drops off to 0.3481 for the QT and 0.2947 for the dichotomized trait
when these numbers are reversed to 600 from the upper Y U = Φ−1(0.94) and 400 from
the lower Y L = Φ−1(0.04) (please see figure 3.8).
To increase the pool of individuals available for the comparison group, asymmetric
thresholds were considered. Power is presented in table 3.7 for a balanced design
of 2,000 individuals for β={0.25, 0.5, 1.0} and 50% causal variants with the upper
threshold set to Y U = Φ−1(0.90). For β=1, the quantile for the lower bound does
not affect the power significantly for the QT. For example, power is 0.7003 for the
symmetric threshold Y L = Φ−1(0.10) and 0.6708 for the threshold Y L = Φ−1(0.50).
However, for the dichotomized trait, the power decreases steadily. When β=0.5, the
power drops of faster for both the QT and dichotomized trait for quantiles qL = 0.30.
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β˜
qL 0.25 0.5 1
0.1 0.0130/0.0150 0.2430/0.2712 0.6535/0.7003
0.2 0.0075/0.0093 0.2077/0.2386 0.6337/0.6864
0.3 0.0049/0.0069 0.1746/0.2074 0.6345/0.6870
0.4 0.0046/0.0054 0.1477/0.1849 0.6097/0.6714
0.5 0.0022/0.0029 0.1230/0.1624 0.6090/0.6708
0.6 0.0014/0.0019 0.1099/0.1551 0.6012/0.6703
0.7 0.0015/0.0023 0.0885/0.1326 0.5673/0.6468
0.8 0.0006/0.0020 0.0655/0.1123 0.5547/0.6456
0.9 0.0007/0.0015 0.0495/0.1018 0.5111/0.6264
Table 3.7: Power under a fixed upper threshold of qU = 0.90 but with varied lower
threshold (qL) and with varying β˜. Balanced sampling is implemented with 1,000 in-
dividuals sampled from each extreme, 50% of the variants causal. Power is repororted
as DT/QT.
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Overall, the extreme trait design (denoted as design 1) provides the optimal power
under the various scenarios considered and is robust to dichotomizing the QT. When
using varied sampling ratios, going beyond a 1:2 sampling ratio does not result in a
significant gain in power. Under the parameter values used, the sampling pool may
be increased by loosening the thresholds without significant power loss.
3.5 Discussion
In the past five years there has been an avalanche of rare variant association testing
methods. Yet an appropriate sampling design is a crucial first step on the road
to identify rare causal variants. I have addressed several practical concerns dealing
with sampling designs. These include selecting appropriate sample sizes and threshold
values as well as using an existing cohort. A number of non-conventional observations
were made for QT based mapping of complex traits. In evaluating the type I error
for the three sampling designs discussed, all designs preserve the type I error when
analyzing the QT as a dichotomized trait. This is due to the use of Fisher’s exact
test which is known to be conservative. However, analyzing the QT as is under all
three designs results with the type I error relatively close to α.Yet, it is still more
advantageous to adapt a quantitative framework for the analysis of complex traits.
When an extreme-trait design is carried-out from an existing cohort, the power for
detecting an association is strongly affected by the rare variant frequencies in each
extreme as well as the size of the cohort. Therefore, selecting an equal number of
individuals from each extreme is not necessarily the most powerful study. Selecting
fewer individuals from the upper extreme and more samples from the lower extreme
is more powerful for identifying variants that increase mean QT values. This is
because the differences in causative variant frequencies are larger when an unbalanced
sampling design is implemented within an existing cohort.
As shown, it is more advantageous to adapt a quantitative framework for the anal-
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ysis of complex traits. At the same time, a careful definition of the phenotype is
necessary along with selecting appropriate threshold to classify individuals. For some
traits, very stringent thresholds may be necessary. For example, autoantibodies to
21-hydroxylase beyond the 99th percentile is a precursor to Addison’s disease, an
autoimmune disorder characterized by adrenal dysfunction [5]. Complex quantitative
traits that have Mendelian subtypes may also need extremely stringent thresholds.
While I have tried to provide a comprehensive analysis of study designs, limitations
must be addressed. Several values of percent causal variants were explored, but it may
be possible that only a fraction of the variants will be causal. In this case, much larger
sample sizes will be required. Though I considered both causal and non-causal vari-
ants, I did not take into effect the directionality of the variant (i.e. protective or risk).
A true signal may be missed if both protective and risk variants are collapsed into
the same group. In our simplified simulations, I did not consider the effects of popu-
lation stratification which can be more problematic for rare variant association than
for common variants. In addition, the use of public sequence data can be a concern
because using controls from different cohorts can inherently consist of heterogeneous
individuals. The study from the Wellcome Trust Case Control Consortium warns
of this potential limitation as there is always the possibility that the control group
may include individuals that are true cases [99]. However, population stratification
can be controlled for in the analysis by the use of principal components. There may
also be difficulty in replicating any association signals because of the heterogeneity
in samples, especially when sampling is not carried out from the same population as
in the original study. A greater concern comes from the sequencing data because if
targets and alignments are very different, the type I error can increase (please see
Chapter 4 for a discussion on this topic).
Designing powerful and robust study designs for the analysis of rare variants is
paramount in the study of complex disorders. Many novel ideas continue to emerge
on dealing with the unique aspects of designing such studies. The extreme trait de-
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sign is a practical design frequently used in QT studies. Studies consistently report
that the extremes are the most informative because they are more likely to be en-
riched with causal variants [17] and that sampling individuals in the middle of the
distribution can dilute any association signal and can lead to reduced power [97].
However, individuals with very extreme trait values may have a different genetic eti-
ology than individuals with less extreme values. Recently, Li et al. (2011) suggested
the approach of trimming the extremes of the distribution and thus using an “almost-
extreme sampling” design to address the heterogeneity that may be present in the
tails [54]. Another option for study designs is to combine extreme trait sampling
schemes with the use of family data. Shi and Rao (2011) have shown that increased
rare variant enrichment can be accomplished by using linkage positive families [95].
This is especially important for traits that have significant heritability.
While the cost of whole-genome sequencing drops, two-stage study designs are also
an alternative design for the discovery of rare variants. By resequencing ten genes in
DNA pools followed by genotyping plausible SNPs in independent samples, Nejenstsev
et al. (2009) reported four independent rare variants associated with Type I Diabetes
[70]. The extreme trait design can also be incorporated into a two-stage design. In
the first stage, only individuals in the extremes are sequenced; in the second stage,
genotyping can be carried out in individuals in the remainder of the distribution (i.e.
non-extremes) [54] or an independent random sample [32].
In conclusion, the results and study designs presented here are aimed at providing
important guidance for implementing efficient sequence based QT studies. While
many challenges remain in the design of appropriate sampling designs, many more
opportunities to understand the etiology of common diseases are on the horizon.2
2The work presented in this chapter is expected to be part of the following paper:
Banuelos R.C., Liu D.J., and Leal S.M. Designing Efficient Sequence-based Genetic Studies
of Quantitative Traits by Incorporating Selective Sampling and Public Cohort Data. In
Progress. [7]
Chapter 4
On the Application of Rare
Variant Association Tests to
Mendelian Traits
For nearly half of the Mendelian diseases and traits found in the Online Mendelian
Inheritance in Man (OMIM) catalog, a causal gene has not been identified. Link-
age analysis has been the traditional method for identifying genes responsible for
Mendelian traits. Linkage analysis requires pedigree data but because Mendelian
traits tend to be very rare, it is difficult to ascertain enough families. Recently, an al-
ternative has been to perform exome sequencing on affected individuals coupled with
a filtering scheme to narrow the list of potential causal variants. The filtering scheme
often involves removing common variants found in public genetic variant databases
(e.g., dbSNP or 1000 Genomes), variants found in the exomes of non-affected fam-
ily members, or variants that Bioinformatics tools have predicted to be neutral or
non-causal. However, such filtering schemes are not fool-proof. Public databases can
include misclassified individuals and variants which can result in false negatives, i.e.,
disregarded disease-causing variants. In addition, many of the Bioinformatics tools
to predict whether a variant is neutral or deleterious are error-prone and the clas-
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sification results vary depending on the tool used [26]. A powerful method to map
genes involved in Mendelian disease is to use rare variant association methods. These
rare variant association methods should be robust to extreme genetic heterogeneity,
i.e., when different genetic loci or alleles within a gene result in the same phenotype.
In this work, one-sided burden-based rare variant association tests are applied to
dominant and recessive traits to determine the power of these tests to detect a rare
variant-Mendelian trait association. A simulation-based analysis is carried out using
different proportions of missing deleterious and neutral variants and varied levels of
genetic heterogeneity. It is shown that one-sided burden tests perform well for small
sample sizes and in the case when there is little to no locus heterogeneity.
4.1 Introduction
Many Mendelian disorders fall under the umbrella of rare [orphan] diseases which
are typically defined as those diseases that affect less than 200,000 individuals in
the U.S. but have dire health consequences [77]. For about half of the diseases and
traits that have been classified as Mendelian or potentially Mendelian in the OMIM
catalog, a causal gene has not been identified. As of April 16, 2013, of the 6,956
phenotypes1 described in OMIM, 3,5702 have some genetic information available [65].
In 2008, the NIH Office of Rare Diseases Research launched the Undiagnosed Disease
Program (UDP) to identify the cause of several rare diseases [77]. The purpose of
this program is to find the genetic causes of 40 hard-to-diagnose diseases per year
using cutting edge sequencing technology [63]. UPD’s primary aim is not to discover
disease-causing genes for monogenic diseases, yet it emphasizes the importance that
single-gene disorders can have to propel knowledge of the mechanisms of disease.
While the etiology of many monogenic traits is not simple, the knowledge gained
from Mendelian traits will enhance our understanding of complex diseases [2].
1Includes traits with a “suspected Mendelian basis” [65].
2This number only reflects autosomal genes.
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4.1.1 On Traditional Linkage Analysis
Linkage analysis has been the classical approach for identifying genes responsible for
Mendelian traits. Linkage analysis is discussed in section 2.5 in more detail. Briefly,
linkage analysis consists of studying the cosegregation of genes within families to
localize a genetic region. Linkage analysis can be carried out in either a model-based
on model-free approach. For the model-based approach, a disease model that includes
the mode of inheritance and frequency of gene variant is required. For the model-based
approach, a disease model need not be specified but information on the frequency of
the loci under consideration is needed. Because linkage analysis often requires many
pedigrees and many Mendelian traits are very rare, it is difficult to obtain or observe
sufficient families that have the trait of interest. In addition, for diseases that occur
sporadically or from de novo mutations, linkage analysis will fail. In these cases, the
linkage analysis step is eliminated and one or more affected individuals undergo whole
genome or exome sequencing.
4.1.2 On the use of NGS
Many of the major genetic discoveries in the past decade have been possible because
of the advances in NGS. In special cases, it is now possible to sequence the genome or
exome of a single individual to localize the disease-causing gene. Because over 85% of
disease-causing variants are in the protein-coding regions of the genome [16], exome
sequencing often suffices. In comparison to the number of individuals to be sequenced
for a linkage analysis, exome sequencing has made it possible to identify the causal
variants of several Mendelian disorders using a modest number of individuals. For
example, by sequencing the exomes of ten individuals, Ng et al. (2010) identified a
de novo mutation in the MLL2 gene as the cause for Kabuki syndrome [73]. Since
then, there have been over 100 disease-causing genes identified for Mendelian diseases
[88]. Exome sequencing has also been successful in identifying genes responsible of
complex traits like schizophrenia and autism spectrum disorders (ASD) [103, 78].
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4.1.3 Exome Sequencing Coupled with Filtering Schemes
When pedigrees are available, a strategy to analyze Mendelian traits can involve
performing linkage analysis followed by targeted or exome sequencing. Yet another
alternative is to use some type of filtering mechanism as described in chapter 2. In
this case, exome sequence data is filtered against public genetic variant databases
such as dbSNP or 1000 Genomes to remove common variants. However, the filtering
strategy based on existing databases is limited because these databases are not free
of diseased individuals and causal variants with reduced penetrance may be observed
in healthy individuals. Yet family data and Bioinformatics tools such as PolyPhen
or SIFT can also be incorporated into the filtering scheme. Family data is useful
because the exomes of affected and unaffected family members can be compared to
search for a potentially causal variant. Bioinformatics tools can be used for variant
functionality prediction or to determine the potential that a variant is damaging. The
drawback of filtering based on the functionality prediction tools is that such tools can
have a low specificity and a large margin of error [26].
To circumvent the problems of traditional filtering schemes, Ro¨delsperger et al. (2011)
proposed a filtering algorithm based on the Identity-By-Descent (IBD) sharing of
relatives, in particular those who share both alleles IBD. In addition to reducing the
candidate gene list, this method provides a quality control check to detect sequencing
errors. While Ro¨delsperger et al. (2011) attempt to counter the low sensitivity of
Bioinformatics tools, their method can have an increased number of false positives
when variants are in linkage disequilibrium [90]. Filtering schemes in general could
be regarded as “Proof-of-principle” approaches [72] given that until recently, there
had not been statistical methods designed specifically for rare variant-Mendelian trait
association [40].
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4.2 Methods
A powerful method to map genes involved in familial forms of disease is to use
rare variant association methods in conjunction with exome sequencing and filter-
ing schemes. The purpose of this work is to analyze several rare variant association
tests that were originally developed for complex traits and apply them to Mendelian
traits. Specifically, this research evaluates the power and type I errors of one-sided
burden-type tests using an extensive simulation approach. Here “burden” does not
refer to the traditional population genetics definition of “genetic burden” or “mu-
tational load” in which selection and fitness effects are considered. “Burden” here
quantifies rare genetic variant counts in affected individuals in comparison to unaf-
fected individuals. To evaluate the robustness of these tests, realistic levels of genetic
heterogeneity both at the locus and allelic level are considered as well as the effects
of missing neutral and causal variants. As an approach to increase the power to iden-
tify the rare causal genetic variant, I also consider unbalanced sampling where the
sampling ratio of affected to unaffected is increased.
4.2.1 Filtering Implementation
Prior to the association testing, I implemented a filtering scheme based on the pipeline
presented in chapter 2. Given that the majority of Mendelian diseases are caused by
rare mutations in the protein-coding regions of genes, I remove common variants with
a MAF > 0.01 and any variants found in existing variant databases. In addition, I
only include nonsynonymous (NS) rare variants as these are more likely to contribute
to disease. The filtering steps are shown in the following flowchart (figure 4.1):
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Exome Sequencing
Remove variants with MAF > 0.01
Remove variants in databases
(e.g., dbSNP, 1000 Genomes)
Keep nonsynonymous variants
List of rare variants
Figure 4.1: Filtering Scheme of Variants for Mendelian Traits [72, 48, 47].
4.2.2 Burden Tests
Type I error and power is evaluated for six commonly used burden-based rare variant
association tests (listed in table 4.1 below and described in detail in §2.3.1). A burden-
based rare variant association tests can be broadly defined as a test that considers
the number (either in count or frequency) of rare variants in affected individuals in
comparison to unaffected individuals [69]. All burden tests were implemented as one-
sided since the interest is in disease-causing genetic variants. However, in section
2.3.2, I discuss the predominant tests used for bi-directional testing when there is an
interest in joint association testing for protective and deleterious variants.
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Burden Test Reference
Aggregated Number of Rare Variants (ANRV) Morris & Zeggini (2010) [67]
Combined Multivariate & Collapsing (CMC) Li & Leal (2008) [53]
Kernel-Based Adaptive Clustering (KBAC) Liu & Leal (2010) [56]
Rare Variants Exclusively in Cases (RVE) Cohen et al. (2004) [17]
Variable Threshold (VT) Price et al. (2010) [86]
Weighted Sum Statistic (WSS) Madsen & Browning (2009) [59]
Table 4.1: Six burden-based rare variant association tests implemented for Mendelian
Traits.
4.3 Simulation Set-up
4.3.1 Genetic Data
The genetic data was generated using the Simulator of Rare Variants (srv) script from
the simuPOP software [83]. To simulate the genetic data, the demographic model for
Europeans as described by Boyko et al. (2008) was used. Boyko et al. (2008)
describe the distribution of the selection disadvantage coefficient s for Europeans as
Gamma(0.206,0.320) [11].
Gene Lengths (bp) 1,500, 5,000, 10,000
Variant Sites Range of 18-50/gene
Mutation Rate 1.8 × 10−8/generation
Model for selection coefficient (s) Gamma(0.206,0.320)
Table 4.2: Settings for simulated data based on Europeans [11, 83]
The purpose of the selection coefficients for variant sites is to differentiate synonymous
variants from nonsynonymous variants. Fitness was modeled under a multiplicative
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model and “a finite-sites mutation model with mutation rate of 1.8 × 10−8” for vari-
ants sites [83]. The gene length considered was 1,500 basepairs (bp). The number of
variant sites per gene simulated selected randomly and was anywhere between 18 to
50 sites per gene.
To mimic errors in the sequencing and genotyping process such as sites not being
captured during genotyping, a fraction of causal/deleterious and neutral sites were
set to missing. Of the two, I expect that the proportion of deleterious sites that are
missing will have a greater impact on the power to detect an association. In addition,
the fraction of causal variants and the proportion of locus heterogeneity each ranged
between 0 to 100%. Finally, allelic heterogeneity was treated as either present (True)
or not (False).
Proportion of Missing Causal Variants 0 to 10%
Proportion of Missing Neutral Variants 0 to 1%
Proportion of Causal Variants 0 to 100%
Proportion of Locus Heterogeneity 0 to 100%
Table 4.3: Specification of noise introduced in the simulation.
4.3.2 Scenarios Considered
Table 4.4 provides a list of the scenarios considered and the simulation set-up of this
research. I consider both dominant and recessive modes of inheritance in this work.
However, I report the results for a dominant trait and note otherwise or when there is
a significant difference in the results for a dominant versus a recessive trait. I evaluate
the type I error and power for sampling an equal number of affected (i.e., cases) and
unaffected (i.e., controls) individuals and compare these results to those of varying
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sampling ratios. The sampling ratios considered range from 1:1 (corresponds to an
equal number of cases and controls) up to the 1:5 ratio which corresponds to sampling
5 controls per affected individual.
Disease Models Dominant, Recessive
Number of Cases 5, 10, 15, 20-50
Number of Controls 5∗, 10, 15, 20-50
Sampling Ratios 1:1 upto 1:5
∗all tests except RVE
Table 4.4: Description of sample sizes considered, as well as scenarios implemented
in the simulation study.
4.4 Results
Since nonsynonymous (NS) variants are more likely to be causal, only NS variants
were considered in the analysis, as shown in the filtering flowchart (figure 4.1). For
all simulations, 2,000 replications were carried out under significance of 0.05, 0.01,
and 0.001. For permutation-based tests, 2,000 permutations were performed with an
adaptive threshold set at 500 once significance was within 10−6 of α.
4.4.1 Evaluation of Type I Error
To evaluate the type I error, the proportion of individuals who are affected (i.e.
“cases”) as a result of the disease locus was set to 0%. In addition, allelic heterogeneity
was set to present (True). To circumvent that the simulation program used did not
allow for the proportion of causal variants to be set to 0%, this proportion was set to
1 × 10−10. No additional noise was introduced, i.e., both proportion of missing causal
and proportion missing neutral variants was set to 0%.
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Equal Number of Cases and Controls
Table 4.5 presents the type I error when an equal number affected and unaffected
individuals are sampled for a dominant trait when α = 0.05. All tests are conservative
in that the type I error remained well below α with WSS being the least conservative
as the sample increases.
Number of Case/Controls
Test 10/10 20/20 30/30 40/40 50/50
ANRV 0.0005 0.0010 0.0035 0.0025 0.0055
CMC 0.0005 0.0020 0.0090 0.0120 0.0190
KBAC 0.0005 0.0010 0.0055 0.0035 0.0065
RVE 0.0005 0.0030 0.0105 0.0120 0.0200
VT 0.0005 0.0015 0.0030 0.0020 0.0050
WSS 0.0025 0.0145 0.0290 0.0400 0.0405
Table 4.5: Type I error comparison for a dominant trait and an equal number of
cases and controls, α = 0.05
When α = 0.001 or α = 0.01, the type I error rates of the six test were similar to those
in table 4.5.
Unequal Number of Cases and Controls
Table 4.6 presents the results for α = 0.05 but with a the number of affected individ-
uals fixed to 10 and allowing the number of unaffected individuals vary between 10
to 50. Observe that the type I error has increased and is affected by the unbalanced
sampling. The type I error of WSS is drastically inflated beyond 0.05 when 30 or
more unaffected individuals are sampled. For the remaining of the tests, the type I
error is still controlled but more of α is spent than in the case when an equal number
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of individuals was sampled. For the recessive trait, all tests except for WSS produce
the same type I errors. WSS was much more conservative for the recessive trait with
all type I errors markedly below 0.05. For example, the type I error for sampling ratio
1:3 for WSS was 0.001.
Number of Controls
Test 10 20 30 40 50
ANRV 0.0005 0.0025 0.0040 0.015 0.0080
CMC 0.0005 0.0025 0.0145 0.0160 0.0165
KBAC 0.0005 0.0025 0.0050 0.0170 0.0090
RVE 0.0005 0.0025 0.0135 0.015 0.0125
VT 0.0005 0.0025 0.0035 0.0155 0.0080
WSS 0.0025 0.0165 0.0985 0.0825 0.0755
Table 4.6: Type I error comparison for a dominant trait under unbalanced sampling,
i.e., for 10 cases and {10, 20, 30, 40, 50} controls, α = 0.05.
In table 4.7, the same unbalanced design of 10 cases to varying number of control
individuals was considered but with α = 0.01. A similar trend is observed as was the
case in previous tables, all tests preserve the type I error with WSS being the least
conservative.
Similarly, when the exact unbalanced scenarios as in tables 4.6 and 4.7 are considered
under a significance level of 0.001, all tests except for WSS perform conservatively
with the type I error markedly below 0.001. For WSS, the type I error is maintained
up to the 1:3 sampling ratio, but increases to 0.0015 and 0.004 for ratios 1:4 and
1:5, respectively. While all tests are conservative as in the previous tables, the tests
are all more strictly conservative by not spending much of α even as the number of
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Number of Controls
Test 10 20 30 40 50
ANRV 0.0000 0.0005 0.0005 0.0015 0.0010
CMC 0.0000 0.0005 0.0020 0.0020 0.0015
KBAC 0.0000 0.0005 0.0005 0.0025 0.0010
RVE 0.0000 0.0005 0.0020 0.0020 0.0015
VT 0.0000 0.0005 0.0010 0.0015 0.0005
WSS 0.0000 0.0015 0.0120 0.0145 0.0220
Table 4.7: Type I error comparison for a dominant trait under unbalanced sampling,
i.e. for 10 cases versus {10, 20, 30, 40, or 50} controls, α = 0.01.
unaffected individuals increases.
4.4.2 Power Analysis
For all scenarios in which the interest is to note the effect of genetic heterogeneity or
noise on the power, the percentage of causal variants was set to 10% unless otherwise
specified.
Exploratory Analysis of Noise Effects using CMC
In order to assess the impact of allelic heterogeneity and missing causal and neutral
variants on the power to detect a rare variant association, the CMC is used because
it is simple and provides analytic power. The simulation is set up for 10 cases and 10
controls with 10% causal variants, 25% locus heterogeneity and allelic heterogeneity
either present or not present and significance of α = 0.001. The first line of table 4.8
is the case of no missing variants (0%). When no there is no allelic heterogeneity
power is 0.6525 but in the presence of allelic heterogeneity the power drops slightly to
0.6440. Lines 2 and 3 present the case of 1% missing neutral variants and 1% missing
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causal variants, respectively. It can be noted that the 1% missing neutral variants
has almost no effect on the power while the 1% missing causal variants causes the
power to drop slightly. In the case of having both 1% missing neutral variants and
1% missing causal variants (line 4), the change in power is not much different than
the case when 1% of the causal variants are missing (line 3).
Allelic Heterogeneity
Case % Missing Present Not Present
1 0% 0.6440 0.6525
2 1% Neutral 0.6520 0.6505
3 1% Causal 0.6355 0.6415
4 1% Neutral, 1% Causal 0.6360 0.6425
Table 4.8: Effects of missing causal and/or neutral variants on the power of the CMC
for 10 cases and 10 controls for 25% locus heterogeneity and 10% causal variants,
α = 0.001.
Under the similar settings, but having no allelic heterogeneity present and only in-
creasing the percentage of missing causal variants, the power drops to 0.6265 and
0.5740 for 2% and 5% missing causal variants, respectively. However, when both the
percentage of missing causal and missing neutral variants increases to 10% each, the
power of the CMC drops to 0.4950, which is most likely driven by the large percentage
of missing causal variants. In the case when allelic heterogeneity is present and there
is 5% missing causal variants and no missing neutral variants, power is 0.5640 which
is not much of a difference in comparison to not having allelic heterogeneity.
In the case that common variants are not excluded and there is no missing variants,
the power is drastically reduced with allelic heterogeneity present or not. Specifically,
keeping all settings the same as in table 4.8, but not excluding the common variants,
77
the power drops to 0.4190 and 0.4205 for allelic heterogeneity present and not present,
respectively.
Equal Number of Cases and Controls
For the case when only five affected individuals are available, I use only the ANRV,
CMC, KBAC, RVE, and VT tests. I first consider the case in which five controls are
available. When no causal or neutral variants are missing and there is between 0%
to 75% locus heterogeneity, both the CMC and the RVE have zero power to detect
association. Under the same scenario, ANRV, KBAC, and VT had power no greater
than 0.085.
Figure 4.2 presents power as the number of affected individuals (i.e., cases) increases.
The same number of unaffected individuals are selected. The settings for this sce-
nario are: allelic heterogeneity is present, 75% locus heterogeneity, and 1% missing
neutral and 1% missing causal variants. The six tests all have a similar trend, with
the KBAC having superior power over the other five tests and WSS having the lowest.
Table 4.9 presents the power to detect an association for 10 affected and 10 unaffected
individuals when there is 10% causal variants, 10% of causal variants are missing (i.e.,
10% of the 10% causal variants are missing), and 10% of neutral variants are set to
missing. The interest here is to note the change in power as the proportion of locus
heterogeneity increases. The significance level was set to 0.001. As one case see, when
the proportion of locus heterogeneity is set to 0 (i.e, a disease results from a single
locus), all tests attain the greatest power. However, setting the proportion of locus
heterogeneity to 0.25 reduces the power for most tests almost by half and further
increasing the locus heterogeneity makes the power approach zero.
Keeping all other parameters the same, but fixing the proportion of locus heterogene-
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Figure 4.2: Power versus number of cases for the six burden tests. An equal number of
affected (cases) and unaffected individuals are selected for a dominant trait. Settings
are: locus heterogeneity fixed to 75%, allelic heterogeneity present, and α = 0.001.
ity to 50% and allowing the percentage of causal variants to vary has a detrimental
effect on power as seen in table 4.10. However, this drop in power is due to the high
locus heterogeneity. What this low power indicates is that high locus heterogeneity
will dilute an association even when the majority of variants under consideration are
causal.
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Proportion of Locus Heterogeneity
0.00 0.25 0.50 0.75
ANRV 0.8805 0.3635 0.0545 0.0020
CMC 0.9140 0.4950 0.0930 0.0025
KBAC 0.9450 0.4290 0.0630 0.0015
RVE 0.9175 0.5005 0.0935 0.0025
VT 0.8805 0.3635 0.0515 0.0005
WSS 0.9065 0.4445 0.0715 0.0010
Table 4.9: Power comparison of the six burden tests for varied levels of locus Het-
erogeneity, fixed proportion of causal variants of 10% for a dominant trait, 10 cases
versus 10 controls, α = 0.001.
Proportion of Causal Variants
0.10 0.25 0.50 0.75
ANRV 0.0545 0.0595 0.0715 0.0595
CMC 0.0930 0.0950 0.0920 0.0975
KBAC 0.0630 0.0660 0.0840 0.0705
RVE 0.0935 0.0955 0.0950 0.0975
VT 0.0515 0.0525 0.0735 0.0560
WSS 0.0715 0.0700 0.0690 0.0735
Table 4.10: Power comparison of the six burden tests, assuming a dominant trait,
with varied levels of the proportion/percentage of causal variants. The locus hetero-
geneity was set to 50%, with 10 cases versus 10 controls, and α = 0.001.
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Unequal Number of Cases and Controls
Figure 4.3 compares the power of sampling an equal number of cases and controls
to the scenario of unequal sampling. All tests of association for 5 affected versus 5
unaffected where significantly underpowered and thus not included in figure 4.3. In
the case when there is no allelic heterogeneity and a low proportion of locus het-
erogeneity (i.e., 20% or less) doubling to 10 controls and tripling (to 15 controls),
the number of controls leads to gains in power for the five tests used. However, this
simulation was based on having no missing causal or neutral variants, thus, it may be
less realistic. But again, in the previous sections, the evaluation of the type I error
and power revealed that locus heterogeneity had greatly affected power regardless of
the number of causal variants present.
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Figure 4.3: Plot of power versus proportion of locus heterogeneity for a dominant
trait, 5 cases and 10 controls (solid line) or 15 controls (dashed line), α = 0.001.
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In table 4.11, the scenario of having 10 affected and 10 unaffected individuals is
compared to the scenario when the number of unaffected individuals is doubled. As
opposed to the previous unbalanced example, here 10% of the causal variants are
missing, 10% of the neutral variants are missing, and locus heterogeneity is set to
25%. In addition, the proportion of causal variants ranges between 10% to 75%. As
expected, increasing the proportion of causal variants has a minimal effect on power.
However, doubling the number of controls from 10 to 20 significantly increases the
power of all test.
10 Cases vs. 10 Controls 10 Cases vs. 20 Controls
Proportion of Causal Variants Proportion of Causal Variants
0.10 0.25 0.50 0.75 0.10 0.25 0.50 0.75
ANRV 0.3635 0.3640 0.3620 0.3715 0.7290 0.7400 0.7325 0.7440
CMC 0.4950 0.4975 0.4865 0.4975 0.7825 0.7910 0.7940 0.8005
KBAC 0.4290 0.4345 0.4275 0.4355 0.8285 0.8350 0.8465 0.8410
RVE 0.5005 0.5025 0.4905 0.5010 0.7860 0.7945 0.7980 0.8035
VT 0.3635 0.3640 0.3620 0.3715 0.7520 0.7580 0.7560 0.7645
WSS 0.4950 0.4975 0.4865 0.4975 0.8485 0.8580 0.8715 0.8725
Table 4.11: Power comparison for the six burden tests and a dominant trait for varied
levels of percent/proportion of causal variants, locus heterogeneity fixed to 25%, 10
cases versus 10 or 20 Controls, and α = 0.001.
4.5 Discussion
In conclusion, the six tests evaluated are very conservative in preserving type I error
when an equal number of individuals are used for either a dominant or recessive trait.
When unbalanced sampling is in place, all tests except for WSS, are increasingly con-
servative as the sampling ratio of affected to unaffected increases. The WSS, on the
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other hand, has inflated type I error for a sampling ratio of 1:3 or greater.
It was also shown that missing causal variants can decrease power whereas the propor-
tion of missing neutral variants does not affect power significantly. In the case when
there is a large portion of causal variants and high locus heterogeneity, the power to
detect an association will be diminished. Finally, power can be increased by doubling
or tripling the number of unaffected individuals in comparison to affected individuals.
Mendelian diseases are supposed to serve as the model for understanding the molecu-
lar mechanisms of disease because of the expected one-to-one correspondence between
a single gene and the phenotype. However, Mendelian traits are complicated by sev-
eral factors. Many Mendelian traits have reduced penetrance or have significant locus
heterogeneity [15]. In the case of reduced penetrance, the issue is then to identify
possible modifier genes that also influence the phenotype [21]. This reduced pene-
trance may suggest that the distinction between Mendelian and complex disease is
not much. In fact, there are several common traits that have monogenic forms such as
early onset Alzheimer’s [82] and hypo-/hyper-triglyceridemia [42]. If this is the case,
another way to interrogate Mendelian diseases could be as the extremes of complex
traits [3].
While exome sequencing has taken away the focus of the family as they primary means
to localize disease-causing genes, family data is still pivotal for monogenic disease
mapping. In particular, linkage peaks can be interrogated by using exome sequencing
[10] or offspring exomes can be compared to parental exomes for identifying de novo
variants [6]. The approach by Ro¨delsperger et al. (2011) on using IBD information in
filtering variants [90] has further demonstrated the value of family data for Mendelian
disease.
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What Does the Future hold for Mendelian Traits?
Until the cost of whole-genome sequencing reaches the coveted $1,000, exome se-
quencing will continue to play a significant role in Mendelian gene discovery. Besides
accelerating discovery of disease-causing genes, exome sequencing has also shown it’s
potential as a diagnostic tool for many Mendelian diseases [48]. The renewed interest
in monogenic diseases may foster advancements in gene mapping and in turn elucidate
our understanding of diseases across the entire spectrum.
Chapter 5
Conclusion and Future Work
Designing an efficient sampling study is a crucial first step for identifying disease-
causing rare variants. In chapter 3, I have addressed several practical concerns deal-
ing with sampling designs for the study of rare variant-complex QT associations. I
discussed selecting appropriate sample sizes and thresholds for selecting individuals
as well as the use of existing public cohorts to increase power. A number of non-
conventional observations were made. In evaluating the type I error for the three
sampling designs discussed, all designs preserve the type I error when analyzing the
QT as a dichotomized trait. This is because Fisher’s exact test was used, which is
known to be conservative. However, analyzing the QT as is, i.e., using the full QT
information, under all three designs results with the type I error relatively close to α.
When an extreme-trait design is carried-out from an existing cohort, the power for
detecting an association is strongly affected by the rare variants frequencies in each
extreme as well as the size of the cohort. Therefore, selecting an equal number of
individuals from each extreme is not necessarily the most powerful study. Selecting
fewer individuals from the upper extreme and more samples from the lower extreme
is more powerful for identifying variants that increase mean QT values. This is be-
cause the differences in causative variant frequencies are larger when an unbalanced
sampling design is implemented within an existing cohort.
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In chapter 4, variant filtering was implemented prior to evaluating the performance of
six burden-based tests (ANRV, CMC, KBAC, RVE, VT, and WSS) for rare variant
association in Mendelian traits. The six tests were very conservative in preserving
type I error when an equal number of individuals were used for either a dominant or
recessive trait. In unbalanced sampling, all tests except for WSS, were increasingly
conservative as the sampling ratio of affected to unaffected individuals increased.
The WSS, on the other hand, had inflated type I error for a sampling ratio of 1:3
or greater. It was also shown that missing causal variants decreased power whereas
the proportion of missing neutral variants did not affect power significantly. When
there was a large portion of causal variants and high locus heterogeneity, the power
to detect an association diminished. Finally, power increased by doubling or tripling
the number of unaffected individuals in comparison to affected individuals.
Because the focus of rare genetic variants as drivers of disease is relatively new, there
are several directions that one can take. Throughout the previous three chapters, I
alluded to potential research questions. Here, I formally discuss recent advancements
and future directions that may hold promise for statistical applications. While the
cost of whole-genome sequencing drops to the expected $1,000, two-stage study de-
signs are an alternative design for the discovery of rare variants. A two-stage design
can be implemented where in the first stage whole or exome sequencing is performed
on a group of individuals for gene discovery and the second stage only involves tar-
geted resequencing or genotyping of the top hits in a different set of individuals.
Two-stage designs have previously been implemented for common diseases. For ex-
ample, by resequencing ten genes in DNA pools followed by genotyping a reduced
number of plausible SNPs in independent samples, Nejenstsev et al. reported four
independent rare variants associated with Type I Diabetes [70]. For common QTs,
the extreme trait design can also be incorporated into a two-stage design. In the first
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stage, only individuals in the extremes can be sequenced and in the second stage,
genotyping can be carried out in individuals in the remainder of the distribution (i.e.
non-extremes) [54] or an independent random sample [32].
There are two major recurring concerns when rare or common variant are discov-
ered. The first is that the variant does not explain enough of the variation in the
trait, as discussed in chapter 2. The second, and the more relevant concern is that
the biological mechanism of the variant is difficult to discern. For the first concern,
a possible explanation is that other genetic factors and mechanisms such as struc-
tural variants (e.g., CNVs) and epigenetic effects also underlie the trait. Interactions
between genetic and/or environmental components can also explain some of the vari-
ability. For the second concern, the biological mechanism will most likely require of
functional analysis. A more practical approach may require a holistic approach such
as pathway-based analysis in which both concerns could potentially be addressed.
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